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Background: The comparative efficacy, and cost-effectiveness, of imiquimod or podophyllotoxin cream,
either alone or in combination with the quadrivalent HPV vaccine (Gardasil®, Merck Sharp & Dohme
Corp., Merck & Co., Inc., Whitehouse Station, NJ, USA) in the treatment and prevention of recurrence
of anogenital warts is not known.
Objective: The objective was to compare the efficacy of imiquimod and podophyllotoxin creams to
treat anogenital warts and to assess whether or not the addition of quadrivalent human papillomavirus
vaccine increases wart clearance or prevention of recurrence.
Design: A randomised, controlled, multicentre, partially blinded factorial trial. Participants were randomised
equally to four groups, combining either topical treatment with quadrivalent human papillomavirus
vaccine or placebo. Randomisation was stratified by gender, a history of previous warts and human
immunodeficiency virus status. There was an accompanying economic evaluation, conducted from the
provider perspective over the trial duration.
Setting: The setting was 22 sexual health clinics in England and Wales.
Participants: Participants were patients with a first or repeat episode of anogenital warts who had not been
treated in the previous 3 months and had not previously received quadrivalent human papillomavirus vaccine.
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Interventions: Participants were randomised to 5% imiquimod cream (Aldara®; Meda Pharmaceuticals,
Takeley, UK) for up to 16 weeks or 0.15% podophyllotoxin cream (Warticon®; GlaxoSmithKlein plc,
Brentford, UK) for 4 weeks, which was extended to up to 16 weeks if warts persisted. Participants
were simultaneously randomised to quadrivalent human papillomavirus vaccine (Gardasil) or saline
control at 0, 8 and 24 weeks. Cryotherapy was permitted after week 4 at the discretion of the
investigator.
Main outcome measures: The main outcome measures were a combined primary outcome of wart
clearance at week 16 and remaining wart free at week 48. Efficacy analysis was by logistic regression
with multiple imputation for missing follow-up values; economic evaluation considered the costs per
quality-adjusted life-year.
Results: A total of 503 participants were enrolled and attended at least one follow-up visit. The mean
age was 31 years, 66% of participants were male (24% of males were men who have sex with men),
50% had a previous history of warts and 2% were living with human immunodeficiency virus. For the
primary outcome, the adjusted odds ratio for imiquimod cream versus podophyllotoxin cream was 0.81
(95% confidence interval 0.54 to 1.23), and for quadrivalent human papillomavirus vaccine versus placebo,
the adjusted odds ratio was 1.46 (95% confidence interval 0.97 to 2.20). For the components of the
primary outcome, the adjusted odds ratio for wart free at week 16 for imiquimod versus podophyllotoxin
was 0.77 (95% confidence interval 0.52 to 1.14) and for quadrivalent human papillomavirus vaccine versus
placebo was 1.30 (95% confidence interval 0.89 to 1.91). The adjusted odds ratio for remaining wart free
at 48 weeks (in those who were wart free at week 16) for imiquimod versus podophyllotoxin was 0.98
(95% confidence interval 0.54 to 1.78) and for quadrivalent human papillomavirus vaccine versus placebo
was 1.39 (95% confidence interval 0.73 to 2.63). Podophyllotoxin plus quadrivalent human papillomavirus
vaccine had inconclusive cost-effectiveness compared with podophyllotoxin alone.
Limitations: Hepatitis A vaccine as control was replaced by a saline placebo in a non-identical syringe,
administered by someone outside the research team, for logistical reasons. Sample size was reduced
from 1000 to 500 because of slow recruitment and other delays.
Conclusions: A benefit of the vaccine was not demonstrated in this trial. The odds of clearance at
week 16 and remaining clear at week 48 were 46% higher with vaccine, and consistent effects were
seen for both wart clearance and recurrence separately, but these differences were not statistically
significant. Imiquimod and podophyllotoxin creams had similar efficacy for wart clearance, but with a
wide confidence interval. The trial results do not support earlier evidence of a lower recurrence with
use of imiquimod than with use of podophyllotoxin. Podophyllotoxin without quadrivalent human
papillomavirus vaccine is the most cost-effective strategy at the current vaccine list price. A further
larger trial is needed to definitively investigate the effect of the vaccine; studies of the immune
response in vaccine recipients are needed to investigate the mechanism of action.
Trial registration: Current Controlled Trials. Current Controlled Trials ISRCTN32729817 and EudraCT
2013-002951-14.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health
Technology Assessment programme and will be published in full in Health Technology Assessment;
Vol. 24, No. 47. See the NIHR Journals Library website for further project information.
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The HIPvac [Human papillomavirus infection: a randomised controlled trial of Imiquimod cream (5%)versus Podophyllotoxin cream (0.15%), in combination with quadrivalent human papillomavirus or
control vaccination in the treatment and prevention of recurrence of anogenital warts] trial compared
two commonly used creams to treat genital warts: 0.15% podophyllotoxin cream (Warticon®;
GlaxoSmithKlein plc, Brentford, UK) and 5% imiquimod cream (Aldara®; Meda Pharmaceuticals, Takeley, UK).
It also investigated whether or not a vaccine used to prevent human papillomavirus infection, quadrivalent
human papillomavirus vaccine (Gardasil®, Merck Sharp & Dohme Corp., Merck & Co., Inc.,Whitehouse
Station, NJ, USA), could help treat warts or prevent them from coming back in patients whose warts had
been cleared.
The HIPvac trial was a randomised controlled trial involving 503 patients with warts attending sexual
health clinics in England and Wales. The creams and the vaccine were well tolerated; there was some
soreness where the cream was applied, but no unexpected side effects.
When deciding which treatment was better, we looked at whether or not the warts had cleared by
16 weeks after starting treatment and, if cleared, whether or not they returned by 48 weeks. We
compared the creams against each other, and the addition of vaccine against no vaccine (a placebo
injection). Patients were allowed to have cryotherapy (freezing treatment) as well, if the investigator
advised this. We also calculated the value for money of each type of treatment.
The two creams were very similar in how well they worked to clear the warts. One difference was that
podophyllotoxin cream worked slightly quicker. The number of patients given cryotherapy was about
the same for both types of cream. We had expected that recurrence of warts after treatment with
imiquimod cream might be less than after treatment with podophyllotoxin cream, but, in fact, the two
creams were similar.
Quadrivalent human papillomavirus vaccine did not improve clearance of warts or reduce the chance
of recurrence, but the result remains inconclusive. If we had been able to recuit 1000 participants as
originally planned, we might have been able to be more certain about whether there was any benefit
of vaccination. Further research would be needed to investigate any possible effect.
The two creams offered similar value for money in treating warts. Giving patients the vaccine in
addition to the cream is not good value for money at its current list price, given the uncertainty about
the benefit it offers.
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Anogenital warts are the second most common sexually transmitted infection diagnosed in sexual health
services in the UK; in 2017, there were 116,342 cases of genital warts treated in England. Over 80% of
cases of genital warts are treated in sexual health services. Despite this, there is a lack of evidence to
guide the choice of treatment. The two most commonly used treatments are self-administered topical
agents podophyllotoxin and imiquimod, but these have never been compared in a large randomised
controlled trial. The main alternative is cryotherapy, which may be combined with topical treatment.
Recurrence of genital warts after any treatment is common, occurring in ≈ 30% of cases. It is reported
that treatment with imiquimod cream results in a lower rate of recurrence than podophyllotoxin.
Quadrivalent human papillomavirus vaccination has been used in the UK national vaccine programme for
girls aged 12–13 years since 2012, and, more recently, in a targeted programme for men aged ≤ 45 years
who have sex with men, and is now given to all boys aged 12–13 years. The vaccine is effective in
preventing infection with human papillomavirus types 6 and 11, which cause 90% of genital warts, as
well as human papillomavirus types 16 and 18, which cause 70% of cervical cancer.Whether or not the
quadrivalent human papillomavirus vaccine has any therapeutic effect in wart clearance, or prevention
of recurrence, is unknown.
Objectives
We aimed to compare the efficacy of imiquimod and podophyllotoxin creams in clearing anogenital
warts by 16 weeks, and to establish whether or not the addition of the vaccine increases wart clearance.
We also aimed to determine whether or not there was a difference in recurrence rate after using imiquimod
or podophyllotoxin creams, and whether or not quadrivalent human papillomavirus vaccine reduces the
recurrence rate after initial clearance in responders to imiquimod or podophyllotoxin when assessed
48 weeks after the start of treatment. Finally, we investigated the cost-effectiveness and cost utility of
imiquimod and podophyllotoxin, both with and without the quadrivalent human papillomavirus vaccine.
Methods
Design
We conducted a randomised, controlled, multicentre, partially blinded factorial design trial. Participants
were randomised equally into four groups: imiquimod plus quadrivalent human papillomavirus vaccine,
podophyllotoxin plus quadrivalent human papillomavirus vaccine, imiquimod plus placebo, and
podophyllotoxin plus placebo. Randomisation was stratified by gender, a history of previous warts
and human immunodeficiency virus status. There was an accompanying economic evaluation.
Setting and participants
The study was conducted in 22 sexual health clinics in England and Wales. Participant inclusion criteria
were patients aged ≥ 18 years presenting with new or recurrent anogenital warts. Exclusion criteria
included treatment for warts in the previous 3 months, previous quadrivalent human papillomavirus
vaccine, contraindications to any of the products (previous intolerance, pregnancy, lactation), a total
wart area of > 4 cm2, patients requiring topical steroids applied to the affected area and patients on
systemic immunosuppressive agents. Patients living with human immunodeficiency virus were initially
excluded, but were included after a protocol amendment in December 2015. Written informed consent
was obtained from all participants.
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Interventions and follow-up
The topical treatments were used in accordance with the licence: 5% imiquimod cream (Aldara®; Meda
Pharmaceuticals, Takeley, UK) applied three times per week for up to 16 weeks and 0.15% podophyllotoxin
cream (Warticon®; GlaxoSmithKlein plc, Brentford, UK) applied twice daily for 3 consecutive days, with
4 days off, for 4 weeks. However, it is common practice to extend podophyllotoxin treatment for up to
16 weeks if a response is seen but warts persist, so this was permitted under the protocol. In addition,
because slower responses may prompt a desire to switch treatment, cryotherapy was permitted after
week 4 at the discretion of the local investigator, who also advised if dose modification was required in
the event of local reactions.
The course of quadrivalent human papillomavirus vaccine (Gardasil®; Merck Sharp & Dohme Corp., Merck
& Co., Inc., Whitehouse Station, NJ, USA) or saline control was started with initiation of topical treatment
(with doses at 8 and 24 weeks). Participants were seen at randomisation and at weeks 4, 8, 16, 24 and 48.
Blinding
The topical treatment was unblinded as a result of the different posology. The vaccination was planned
to be double-blind, but difficulties with sourcing and filling a matching placebo syringe led to a partially
blinded design being adopted. The pre-filled syringes were presented in blinded packaging and the
vaccine dose was administered by an unblinded member of the clinical team who was not involved in
any study-related assessments.
Randomisation
Randomisation was carried out using minimisation with a random element, with gender, previous
occurrence of warts and trial site as stratification factors. Human immunodeficiency virus status was
added as a stratification factor when the entry criteria were changed. Participants were randomised
1 : 1 to either topical treatment and 1 : 1 to quadrivalent human papillomavirus or placebo. A secure
online service (Sealed Envelope™; Sealed Envelope Ltd, London, UK) provided computer-generated
participant identifiers and the trial arm allocations.
Outcome measures
The primary outcome was a combination of wart clearance at week 16 and remaining wart free at
week 48. The two components of the primary end point were considered as factor-specific, clinically
important secondary outcomes: for topical treatment, the proportion that were wart free at week 16;
for vaccination, the proportion of those with wart clearance at week 16 and remaining wart free
between week 16 and week 48. Additional secondary outcomes were specified, including the proportion
that were wart free at the end of the assigned treatment course (4 or 16 weeks), the proportion that
were wart free at week 16 without receiving additional treatment, the proportion that experienced
complete wart clearance at any time up to week 48, adverse events, health-related quality of life and
symptom scores.
The economic evaluation considered, as the base case, the incremental costs per quality-adjusted life-year
gained by each intervention. In additional analyses, we used, separately, the components of the combined
primary end point of the trial as the denominators in cost-effectiveness analysis, that is the incremental
costs per additional patient clearing warts by week 16 and avoiding recurrence up to 48 weeks after
starting treatment.
Sample size
The trial was originally designed with a sample size of 1000 participants. With 20% loss to follow-up,
800 participants would contribute primary outcome data. If the proportion achieving the primary end
point in the less favourable topical treatment group was 35% (assuming a wart clearance rate of 50%
and a 30% subsequent recurrence rate), this would have provided 80% power (at the 5% significance
level) to detect an increase to 45% achieving the primary end point with the better treatment.
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This corresponds to an odds ratio of 1.52. The same effect size would also have been detectable if
vaccination reduced the recurrence rate from 30% to 10%, while leaving the wart clearance rate
unchanged at 50%.
After failing to achieve the necessary recruitment rate, a revised sample size of 500 participants was
agreed with the funder in February 2016. With 15% loss to follow-up, this would now provide only
52% power (at the 5% level) to detect the prespecified difference in the combined primary end point.
However, it would still provide 80% power (at the 5% level) to evaluate each of the two components of
the primary outcome: for the week 16 topical treatment outcome, a difference of 14% in wart clearance
(57% wart clearance in the imiquimod group vs. 43% wart clearance in the podophyllotoxin group) could
be detected, and, for the week 48 vaccine outcome, a difference of 16% in recurrence (12% recurrence
in the vaccine group vs. 28% recurrence in the placebo group) could be detected. These differences
were considered to be clinically important and sufficient to justify continuing the trial.
Protocol changes
In addition to the reduction in trial size, a number of other changes to the trial design were made.
Withdrawal of pharmaceutical company support required a switch from a double-blind hepatitis A
vaccine comparator group to a saline placebo and a partially blinded design. People living with human
immunodeficiency virus were initially excluded, but the entry criteria were changed to allow enrolment
of those stable on antiretroviral treatment or those with a normal cluster of differentiation 4 count.
Data collection and management
Data were centrally entered into a MACRO v4.0 (Elsevier, Amsterdam, the Netherlands) database
with internal validation checks to improve data quality; data queries were resolved by site staff before
database lock and final analysis.
Statistical methods
As detailed in the statistical analysis plan that was confirmed before the analyses were carried out, missing
outcome data were imputed using multiple imputation with chained equations and the analyses for all
primary and secondary outcomes were performed on multiply imputed data sets with results combined
using Rubin’s rules. The details of the variables included in the multiple imputation models and the number
of imputations carried out are detailed in Chapter 2. All analysis models included gender, previous
occurrence of warts, human immunodeficiency virus status and both treatment factors (topical treatment
and vaccination) as covariates; trial site was included as a random effect. Adjusted treatment effect
estimates, 95% confidence intervals and two-sided p-values were reported for each outcome measure.
All the analyses were conducted on a modified intention-to-treat basis such that all consented randomised
participants for whom at least one follow-up visit was available were included in the analysis, regardless
of their adherence to treatment. The HIPvac [Human papillomavirus infection: a randomised controlled
trial of Imiquimod cream (5%) versus Podophyllotoxin cream (0.15%), in combination with quadrivalent
human papillomavirus or control vaccination in the treatment and prevention of recurrence of
anogenital warts] trial was a pragmatic study concerned with the effectiveness and acceptability of both
topical therapy and quadrivalent human papillomavirus vaccination.
The primary analyses for both factors (podophyllotoxin vs. imiquimod and quadrivalent human
papillomavirus vaccine vs. placebo) were based on comparisons at the margins of the 2 × 2 table so
that all participants randomised to podophyllotoxin were compared with all participants randomised
to imiquimod and all participants randomised to quadrivalent human papillomavirus vaccine were
compared with those randomised to placebo.
A substantial interaction between topical treatment and vaccination was not anticipated; results from a
four-arm analysis (in which each of the four treatment groups were regarded as a separate treatment arm)
are presented (see Table 10). A model including an interaction between the two factors was fitted as a
secondary analysis.
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Economic evaluation
The economic evaluation was conducted from the perspective of the NHS over the trial duration
(i.e. without discounting future time preferences, because of a trial length of < 1 year). Apart from the
characteristics outlined above, the economic evaluation explored a range of different aspects of the trial,
including a comparison of quadrivalent human papillomavirus vaccine versus placebo and imiquimod versus
podophyllotoxin; the difference over 16 weeks and 48 weeks; the difference between utility values mapped
to the EuroQol-5 Dimensions, three-level version, and those obtained with the EuroQol-5 Dimensions,
five-level version; the difference between three different study populations (the intention-to-treat
population, the population that had never changed the allocated topical treatment and the complete-case
population based on the utility scores); and the missing-at-random assumption for missing utility values.We
also explored three different cost scenarios for the episodes of health-care visits in the absence of conclusive
information and conducted a threshold analysis. The uncertainty associated with the imputation and the
study sample was explored using a combined bootstrapping approach, and we calculated the probability
of each treatment option being cost-effective based on the net monetary benefit, which can be defined
as the difference in the value of monetised economic benefits (health outcomes and costs saved) in each
arm, where the health outcome is expressed in monetary units, using a range of willingness-to-pay
thresholds (£0–50,000 per quality-adjusted life-year).
Results
Baseline characteristics
Between November 2014 and January 2017, 506 participants were consented and randomised;
503 participants attended at least one follow-up visit. The mean age was 31 years, 66% of participants
were male (24% were men who have sex with men), 50% of participants had a previous history of
warts and 2% were known to be living with human immunodeficiency virus. The groups were well
balanced at baseline.
Primary outcome
The primary outcome of the study was a combination of being free of warts at week 16 and remaining
wart free at week 48 from the start of treatment. This was achieved in 35 out of 101 participants
(35%) allocated to receive imiquimod and quadrivalent human papillomavirus vaccine, 38 out of 99
(38%) allocated to podophyllotoxin and quadrivalent human papillomavirus vaccine, 25 out of 98 (26%)
allocated to imiquimod and placebo vaccine and 30 out of 99 (30%) allocated to podophyllotoxin and
placebo. The denominator in each group is those participants who provided follow-up data at week 48.
For the primary outcome of wart free at week 16 and remaining wart free at week 48, the adjusted odds
ratio for imiquimod relative to podophyllotoxin was 0.81 (95% confidence interval 0.54 to 1.23). This
confidence interval provides no evidence of a difference between the topical treatments. Furthermore,
the interval excludes a clinically meaningful treatment benefit of imiquimod over podophyllotoxin
(odds ratio 1.52), but is consistent with a meaningful benefit of podophyllotoxin over imiquimod (odds
ratio 1/1.52 = 0.66). For the quadrivalent human papillomavirus vaccine versus placebo comparison,
the adjusted odds ratio was 1.46 (95% confidence interval 0.97 to 2.20), so no effect has been shown.
However, the lower boundary of the confidence interval was very close to 1, which suggests that the
vaccine may improve the primary outcome, although this is inconclusive. Furthermore, this confidence
interval includes an odds ratio of 1.52, which would have been a clinically meaningful effect of vaccine,
as specified in the study design.
Secondary outcomes
The two components of the primary outcome were considered as important secondary outcomes,
particularly given the reduced size of the trial. The first of these was the analysis of wart clearance at
week 16: adjusted odds ratio 0.77 (95% confidence interval 0.52 to 1.14) for imiquimod versus
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podophyllotoxin and adjusted odds ratio 1.30 (95% confidence interval 0.89 to 1.91) for quadrivalent
human papillomavirus vaccine versus placebo. These differences were not significant but favour
podophyllotoxin and vaccine. For remaining wart free at week 48 (in those who were wart free at
week 16), the adjusted odds ratio of 0.98 (95% confidence interval 0.54 to 1.78) for imiquimod versus
podophyllotoxin provides no evidence of a difference in recurrence rate between the two topical
treatments. For the vaccine versus placebo comparison, there was an adjusted odds ratio of 1.39
(95% confidence interval 0.73 to 2.63). It is noted that the possible benefit of vaccine seen in the
primary outcome analysis is a reflection of consistent effects seen in the two components.
Economic evaluation
The economic evaluation demonstrated that the costs and resource use were similar between the
topical treatments, and there was a non-significant reduction in treatment costs with the quadrivalent
human papillomavirus vaccine compared with placebo. The results were similar for both time frames.
Patients had generally high health-related quality of life scores at baseline, with a clustering of responses
on a few (very high) health states and overlapping confidence intervals. The values mapped on to the
EuroQol-5 Dimensions, three-level version, were slightly lower than those obtained for the EuroQol-5
Dimensions, five-level version.
With the EuroQol-5 Dimensions, three-level version – the measure currently preferred by the National
Institute for Health and Care Excellence – the treatment option with the highest (≥ 50%) probability
of being cost-effective was podophyllotoxin without quadrivalent human papillomavirus vaccine across
the range of willingness-to-pay thresholds of £0–50,000 per quality-adjusted life-year, which increased
to > 75% with the EuroQol-5 Dimensions, five-level version.
The incremental cost-effectiveness of adding the quadrivalent human papillomavirus vaccine to
podophyllotoxin exceeded £80,000 per quality-adjusted life-year and thus cannot be considered
cost-effective at the current list price of the vaccine at conventional willingness-to-pay thresholds.
The factorial cost-effectiveness analysis gave negative incremental quality-adjusted life-years at higher
incremental costs for the quadrivalent human papillomavirus vaccine. In addition, podophyllotoxin was
always associated with positive incremental quality-adjusted life-years and fewer incremental costs
than imiquimod (i.e. podophyllotoxin was cost-saving and dominated imiquimod). These findings were
robust to different assumptions for imputing missing utility values.
The threshold analysis showed that adding quadrivalent human papillomavirus to podophyllotoxin
could be considered cost-effective if the price of the quadrivalent human papillomavirus vaccine was
substantially reduced below its list price, which is the case for the national human papillomavirus
vaccine programme.
In the incremental analysis, the most cost-effective option per additional patient for clearing warts by
week 16 and avoiding recurrence up to 48 weeks after starting treatment was, again, podophyllotoxin
with placebo. Further health gains were achievable with podophyllotoxin and quadrivalent human
papillomavirus at between £1280 and £1350 per additional patient remaining wart free by week 16.
For the patients who avoided recurrence by week 48, further health gains were achievable with
imiquimod plus placebo and imiquimod plus quadrivalent human papillomavirus (between £1400 and
£2300 vs. between £2500 and £3000 per additional patient avoiding recurrence, respectively).
Conclusions
The trial had to be reduced in size from that originally proposed. A benefit of vaccine was not demonstrated
in this trial. The odds of clearance at 16 weeks and remaining clear at 48 weeks were 46% higher with the
vaccine, and consistent effects were seen for both the wart clearance and recurrence component outcomes,
but these differences were not statistically significant. Imiquimod and podophyllotoxin had similar efficacy
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in wart clearance, although the comparative confidence interval was wide. The trial results do not support
earlier evidence of a lower recurrence rate with use of imiquimod compared with podophyllotoxin. The
cost–utility analysis demonstrated that podophyllotoxin without quadrivalent human papillomavirus vaccine
is likely to be the most cost-effective strategy at the current vaccine price, and adding quadrivalent human
papillomavirus to podophyllotoxin may be cost-effective at a greatly reduced vaccine price.
Future work
Since this trial started, two randomised controlled trials of quadrivalent human papillomavirus vaccine
versus placebo have been commenced to determine the effect on wart recurrence. There have been no
further studies of the potential therapeutic effect; a trial larger than this one is required to definitively
investigate this effect. Studies of the immune response in vaccine recipients with genital warts could
elucidate a possible mechanism of action.
Trial registration
This trial is registered as ISRCTN32729817 and EudraCT 2013-002951-14.
Funding
This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 24, No. 47.
See the NIHR Journals Library website for further project information.
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Genital warts are benign lesions that present as lumps or raised plaques in the skin of the anogenital area.
They are usually painless, but can cause irritation or bleeding. More commonly, they cause emotional
distress, which is exacerbated by the need for prolonged, time-consuming and uncomfortable treatment.
Relapse after apparently successful treatment occurs frequently. Surgery may be required in persistent or
severe cases. About 90% of genital warts are caused by human papillomavirus (HPV) types 6 or 11, which
are sexually transmitted.1 These viruses are not believed to be associated with a risk of cervical or other
genital cancer, and are therefore termed ‘low risk’. Other HPV types, particularly HPV types 16 and 18, are
associated with a risk of cancer; indeed, these or one of the other ‘high-risk’ types are found in almost every
case of cervical squamous cell carcinoma. However, high-risk types do not cause benign genital warts.
Of the 116,342 episodes of new or recurrent genital warts treated in sexual health services in England
in 2017, 49% were recurrent episodes.2 First-episode genital warts accounted for 15% of new sexually
transmitted infections (STIs) diagnosed, making it the second most common STI after chlamydia
infection. NHS treatment costs for anogenital warts in 2016 were estimated at £14M, of which about
£6M was to treat recurrent episodes.3
Since 2012, the HPV vaccine programme in 12- to 13-year-old girls has used the quadrivalent human
papillomavirus (qHPV) vaccine, which is effective against HPV types 6 and 11, as well as the high-risk
HPV types 16 and 18. The incidence of anogenital warts in young adults is beginning to fall, but the
current programme is not predicted to result in elimination; therefore, effective treatment for warts
will continue to be required.
The best first-line topical treatment for anogenital warts has not been established in clinical trials,
so treatment guidelines lack a firm basis for their recommendations. The HPV vaccine is indicated to
prevent infection; a therapeutic effect, although suggested, has not been established in a clinical trial.
The most clinically effective, and cost-effective, treatment for anogenital warts remains uncertain, so
clinical guidelines lack a secure evidence base.4–6 Cryotherapy with liquid nitrogen can be used to treat
anogenital warts. This treatment may be effective with a single application, but it requires equipment
and facilities usually available only in specialist community settings and hospitals, and also requires
appropriately trained staff. Repeated clinic attendance is often required for further applications
of cryotherapy. Given the inconvenience for patients, and the burden it places on limited health
service resources, most cases of warts are now treated with self-administered topical agents, of which
podophyllotoxin (PDX) is the most common.7 The plant extract podophyllin was used in clinics as an
unlicensed product for the treatment of warts for many years. The standardised, purified product,
PDX, is licensed and can be used safely by patients at home. It is more effective than podophyllin.
PDX is a chemotherapeutic agent that probably acts by prevention of tubulin polymerisation required
for microtubule assembly and by inhibition of nucleoside transport through the cell membrane. This
leads to inhibition of growth of virally infected cells. Licensed forms include a cream and solutions.
Efficacy has been demonstrated in randomised trials.7–15 The cream Warticon® (GlaxoSmithKlein plc,
Brentford, UK) contains the active compound at a concentration of 0.15%, whereas the solution is
0.5%. The cream is considered to be easier to apply, at least at some anatomical sites, and may be better
tolerated. The consensus has been that the efficacy of the cream and the solution are similar, although
a recent systematic review and meta-analysis concluded that the solution is slightly more effective.16
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The main alternative topical treatment is imiquimod (IMIQ). This is more expensive, although the price
difference has reduced since the expiry of patent protection. Nonetheless, IMIQ is reserved in many
clinics, and in guidelines, as a second-line therapy. IMIQ is available as a 5% cream (Aldara®; Meda
Pharmaceutical, Tekely, UK). Some studies have suggested that IMIQ is associated with a lower
recurrence rate after complete wart clearance, possibly as a result of its mode of action as an immune
response modifier.17,18 It is a toll-like receptor 7 agonist and stimulates tissue macrophages to release
interferon alpha and other cytokines, which trigger a local cell-mediated response. IMIQ has no direct
antiviral activity. The response to treatment may be slower than with PDX, and the licensed treatment
duration is longer, at up to 16 weeks. Most patients will show a response by 8 weeks.
The efficacy of IMIQ compared with placebo or other treatment modalities has been investigated in
a number of trials.15,19–26 However, the efficacy of PDX and IMIQ as initial therapies for anogenital
warts have never been compared in an appropriately powered trial.5 The only randomised trial that
directly compared these two agents was underpowered (n = 51) and did not report recurrence rates.15
The clearance rates were similar but with wide confidence intervals (CIs): 75% clearance with IMIQ
compared with 72% with PDX (95% CI 53% to 89% and 52% to 86%, respectively).
A systematic review of wart treatment undertaken for European guidelines for the treatment of genital
warts5 suggested that PDX has a similar rate of initial clearance to IMIQ (43–70% at 4 weeks compared
with 55–81% clearance at 16 weeks, respectively), but that recurrence rates may be lower with IMIQ
(6–26% at 6 months for IMIQ compared with 6–55% at 8–12 weeks for PDX). The wide variation
between reported studies may be related to differences in study design, including the outcome measures
and timing. The review5 found no evidence for any single therapy being superior overall, largely owing to
the lack of high-quality comparative studies. Those studies reported were heterogeneous in design, and
often had high loss to follow-up. Large, well-designed randomised studies are required to make a firm
recommendation on treatment. UK national guidelines recommend that the choice of first-line therapy
is based on patient preference, morphology and distribution of lesions, with a clinic treatment algorithm
to guide treatment.4
The HPV vaccine is indicated to prevent infection; a therapeutic effect, although suggested, has not been
established in a clinical trial. It is not known if the clearance rate of anogenital warts is increased when
a HPV types 6 and 11 vaccine is given at the time of initiating either a topical treatment or cryotherapy.
Similarly, whether or not recurrence of warts after clearance is reduced by the HPV vaccine has not
been established.
Vaccines are currently licensed to prevent only HPV-associated anogenital warts and cancers; the qHPV
vaccine Gardasil® (Merck Sharp & Dohme Corp., Merck & Co., Inc.,Whitehouse Station, NJ, USA) is the
only vaccine that also protects against the low-risk genotypes 6 and 11.This vaccine has been used in the
national vaccination programme in the UK since 2012 for girls aged 12–13 years.Whether or not the vaccine
has a therapeutic or secondary preventative effect for anogenital warts (or other HPV-associated diseases)
has yet to be determined. Although there is no randomised controlled trial (RCT) evidence yet, there are
other types of evidence that there may be a therapeutic or secondary preventative effect.
There are case reports that clearance of anogenital warts may have been enhanced by the qHPV
vaccine.27,28 There is some evidence from placebo-controlled vaccine trials that found that women
who are HPV seropositive but HPV deoxyribonucleic acid (DNA) negative for at least one HPV type
at trial entry were protected against subsequent disease related to the HPV type to which they were
previously exposed.29 In addition, women with genital lesions treated surgically while in the vaccine
trial were less likely to develop recurrent or progressive disease if they were in the vaccine arm than
if they were in the placebo arm of the trial.30 Patients with anogenital warts or genital intraepithelial
neoplasia (cervical intraepithelial neoplasia, vulval intraepithelial neoplasia or vaginal intraepithelial
neoplasia) have been shown to be at risk of reinfection with the same or different HPV types as well
as relapse of existing infection.31,32 Limited evidence also suggests that the qHPV vaccine (Gardasil)
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may reduce recurrences of respiratory papillomatosis in children,33 a condition usually caused by
low-risk HPV types, principally 6 and 11. Similarly, anal intraepithelial neoplasia,34 caused by high-risk
HPV types included in the vaccine, may be less likely to recur in vaccine recipients. Finally, vaccine
antibody responses are stronger than those induced by natural infection;35 this means that boosting
the immune response with vaccine could reduce the persistence of HPV types 6 and 11 infection and,
therefore, the rate of disease recurrence. As an unmet need, the ability of vaccine to reduce the
recurrence rate would be of greatest value to patients, given the estimated 30% recurrence seen with
all treatments. Recurrence of warts after clearance by topical treatment is also the part of the disease
process in which the vaccine is most likely to have activity.
Studies of the treatment cost and quality-of-life impact of genital warts, as well as economic analyses
of vaccinating against HPV infection, have been conducted.3,36,37 These studies have documented
significant negative impacts on quality of life and substantial health-care service costs. The cost of
IMIQ remains higher than that of PDX. If the effectiveness of IMIQ proves superior, then an economic
analysis would allow an assessment of the maximum cost difference that would warrant its use as a
first-line therapy. All available treatments have significant failure and recurrence rates. By maximising
initial response rates and reducing recurrence rates using first-line self-administered treatment,
a RCT has the capacity to reduce this health and quality-of-life burden for patients and improve
cost-effectiveness, now and in the future. Vaccination would add to the cost of treatment of patients
with anogenital warts. If efficacy is demonstrated, an economic analysis could determine at which level
the increased treatment costs would be justified by reduced future health-care costs and improved
quality of life related to persistent or recurrent disease.
Objectives
The trial assessed the comparative efficacy of the two main topical treatments in current use, 0.15% PDX
cream (Warticon) and 5% IMIQ cream (Aldara), and investigated the potential therapeutic benefit of a
qHPV vaccine (Gardasil) in the management of patients with anogenital warts. The trial also evaluated
the relative costs of the two topical treatments, as well as of the novel use of qHPV vaccination for both
treatment and secondary prevention. The adoption of a pragmatic trial design with broad entry criteria
for the comparison of the two topical therapies means that the results can be generalised to the large
number of patients treated each year who present with anogenital warts. The topical therapies assessed
and the potential (in the protocol) to use supplementary cryotherapy were closely aligned with current
clinical practice.
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This chapter is adapted from Murray et al.38 This article is distributed under the terms of the CreativeCommons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/),
which permits unrestricted use, distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons
license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Design
The study was a randomised, controlled, partially blinded 2 × 2 factorial-design trial of treatment for
anogenital warts with an accompanying economic analysis. All participants received active, topical
treatment with either PDX cream or IMIQ cream. They also received a course of qHPV vaccine or
saline placebo injections. Participants were allocated in equal numbers to the four combinations of the
two topical treatments and the vaccine or placebo: IMIQ cream plus qHPV vaccine, PDX cream plus
qHPV vaccine, IMIQ cream plus saline placebo injection and PDX cream plus saline placebo injection.
The primary outcome was clearance of warts at 16 weeks and remaining clear until the end of follow-up
at 48 weeks. Analysis of the primary outcome was based on logistic regression. In the economic evaluation,
we investigated the cost-effectiveness and cost–utility of the two topical treatments and the qHPV vaccine.
Ethics
The trial protocol was reviewed by the Oxfordshire Research Ethics Committee B (reference number
13/SC/0638) and received a favourable opinion on 3 February 2014. Amendments to the protocol
were subject to further review, including the decision to reduce the size of the trial, with its attendant
impact on the likelihood of reaching a definitive conclusion.
Patient and public involvement
The research proposal was reviewed by a patient representative at the Mortimer Market Centre
(Central and North West London NHS Foundation Trust) before funding submission. The design of the
study was discussed with a patient user group in the human immunodeficiency virus (HIV) clinical
service during the development of the protocol. A lay representative was on the Trial Steering
Committee (TSC).
Setting
The trial was carried out in 22 sexual health clinics in England and Wales (see Appendix 1 for a list of
participating sites). Sexual health clinics in the UK are open-access services, with most patients being
self-referred. Approximately 80% of cases of genital warts treated in the NHS are treated in sexual
health clinics.
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Participants
The eligibility criteria for participants were adults, aged ≥ 18 years, presenting to participating clinics
with external anogenital warts that, in the opinion of the investigator, could be appropriately treated
with either self-administered IMIQ cream or self-administered PDX cream. Patients with a first episode
of warts, and patients for whom this was a repeat episode, were eligible provided that they had not
received treatment for warts in the previous 3 months.
Other exclusion criteria included patients who had previously had qHPV vaccine (but having had bivalent
HPV vaccine was not an exclusion criterion). Patients with any contraindication to any of the products
were excluded, which included previous intolerance to vaccines, pregnancy and lactation. Those with a
total wart area of > 4 cm2 were excluded because the 0.15% PDX cream product information advice is to
treat more extensive lesions only under medical supervision. Patients requiring topical steroids applied
to the affected area, or on systemic immunosuppressive agents, were also excluded.
Initially, participants with known HIV infection were excluded, on the grounds that wart treatment and
vaccine responses were reported to be impaired, with implications for the sample size. But, in December
2015, the entry criteria were modified to include patients living with HIV who were stable on antiretroviral
treatment and had a cluster of differentiation 4 (CD4) count of > 350 cells/µl and those not on treatment
with a CD4 count of > 500 cells/µl. This would exclude only those with more severe immunosuppression.
Current evidence indicates that, in the majority of patients with HIV infection with well-preserved or
restored immune markers, vaccine and treatment responses are not substantially impaired.39–41
Interventions
The two topical treatments compared in the trial were 5% IMIQ cream and 0.15% PDX cream, both
licensed products for the treatment of anogenital warts.
Participants randomised to IMIQ applied the cream to the warts in accordance with the licence, that is,
3 days of the week (every other day) at bed time, left on overnight, and the area of application washed
after 6–10 hours. Duration of treatment was up to 16 weeks.
For participants randomised to PDX, the instruction was to apply the cream twice per day for 3 consecutive
days followed by no treatment for 4 days, in weekly cycles. The licensed treatment duration is 4 weeks,
but it is common practice to extend this period if there is a response to therapy. In the trial, we therefore
allowed continued use of PDX cream for up to 16 weeks. No crossover of the topical treatment was
permitted before 16 weeks.
Dose modifications of topical treatment were permitted if required for tolerability. For PDX, the
weekly cycle of treatment could be postponed for 3 days, or longer if required, in which case it
was restarted once daily. For participants unable to tolerate the standard regimen for IMIQ, the
advice was to reduce the frequency of dosing to twice per week, and then to once weekly if
tolerability was not improved. Any skin reaction requiring dose modification was reported as an
adverse event (AE).
The qHPV vaccine was administered according to the schedule licensed for the prevention of HPV
infection, with three doses administered at the time of randomisation and at 8 and 24 weeks. The
vaccine volume is 0.5 ml and is presented in a pre-filled syringe. The placebo comparator for the
vaccine was 0.5 ml of normal saline.
METHODS
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To retain participants in the trial without crossover of topical treatment before 16 weeks, adjunctive
cryotherapy was permitted from week 4 (visit 2) onwards if, in the opinion of the investigator, this was in
the best interests of the patient, and after assessment of the response to topical treatment to date.
Randomisation
Participants were randomised to one of four groups:
1. IMIQ cream plus qHPV vaccine
2. PDX cream plus qHPV vaccine
3. IMIQ cream plus saline placebo injection
4. PDX cream plus saline placebo injection.
Allocation to the groups was carried out using minimisation with a random element, with gender, previous
occurrence of warts and trial site as stratification factors. HIV status was added as a stratification factor
when the eligibility criteria were changed. Participants were randomised 1 : 1 : 1 : 1 to the four groups.
Trial participant number and randomisation group allocation were computer-generated and accessed by
a secure online facility (Sealed Envelope™; Sealed Envelope Ltd, London, UK), which required entry of
participant characteristics to allow the minimisation process to be completed.
Blinding
The differences in posology of the two topical treatments made a blinded comparison impractical.
Therefore, the creams were dispensed in unblinded original packs.
The qHPV vaccine and saline placebo were dispensed in blinded packaging comprising an opaque
plastic sleeve inside a cardboard box labelled with the trial details and a unique pack code number.
Both were in pre-filled syringes, but it was not possible to source matching syringes to produce a fully
blinded placebo. Therefore, the vaccine or placebo was administered by a member of staff who was not
part of the trial team involved in the assessment of the participant.
Recruitment and consent
Members of the clinical team at participating clinics identified potential trial participants and referred
them to the trial team. Participants were provided with the information sheet and gave written
informed consent. Most participants were recruited at the same visit, but, if more convenient for the
participant, the first visit, and treatment, were delayed for up to a few days.
Baseline visit
The baseline assessment included a record of previous wart episodes and treatments, history of STIs
and comorbidities, history of recent sexual contacts, concomitant medication and a quality-of-life
questionnaire [EuroQol-5 Dimensions, five-level version (EQ-5D-5L)].
The location of warts present was recorded and the approximate number of warts present was recorded
in categories: 1–5, 6–10, 11–20 and > 20. The maximum diameter of the largest wart was recorded,
measured against a size gauge. A symptom-directed general physical examination was performed,
if appropriate.
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A swab from the wart lesions and a blood sample were collected and archived for mechanistic studies,
subject to separate review and funding. The details of the baseline and follow-up assessments are
tabulated in Appendix 2.
Randomised treatments were then prescribed or administered and participants were supplied with
information on their use, risks and side effects. Participants were offered safer-sex advice and access
to other sexual and reproductive health services as per routine care. For women of child-bearing
potential, a pregnancy test was performed. Diary cards were provided to the participant to remind
them when the treatment should be applied and to record its use, if and when warts cleared and any
symptoms related to the topical treatment. These were reviewed at follow-up study visits.
Follow-up assessments and treatment
Trial follow-up was for 48 weeks, with scheduled visits at weeks 4, 8, 16, 24 and 48. Presence of warts
was determined on examination by a member of the trial clinical team at each of these visits and at
any unscheduled visit. Further topical treatment was supplied according to the randomised allocation
at weeks 4 and 8 if required. Blinded vaccine or placebo was administered at weeks 8 and 24,
regardless of the response to topical treatment.
If warts recurred within the first 16 weeks, the participant was prescribed the treatment to which they
were randomised at baseline. Participants were asked to return to the clinic early for an extra visit if
they noticed a recurrence of warts after complete clearance so that this could be documented and a
swab from the new or recurrent lesion collected.
Cryotherapy was offered at the discretion of the local investigator if this was considered to be in the
best interests of the patient and after assessment of response to topical treatment to date. Investigators
were encouraged not to give cryotherapy before 4 weeks to allow for assessment of the initial response
to topical treatment alone in all cases.
If a participant was unable to tolerate the allocated treatment during the first 16 weeks, and after
dose modifications as appropriate, alternative treatment could be administered at the discretion of the
investigator. For the purposes of the trial, use of alternative treatments other than additional weeks
of PDX or cryotherapy before 16 weeks was considered a topical treatment failure. In the event of
treatment failure, participants were still followed up and received vaccine or placebo in accordance
with protocol.
After week 16, topical treatment for any persistent or recurrent warts was at the discretion of the
investigator, including a switch to the other randomised topical treatment.
The timing of wart clearance was recorded for the secondary outcomes analysis. If there were
additional visits for clinical care between weeks 16 and 48, a record was made of whether or not warts
were present.
Routine visits included a review of adherence to the treatment regimen, tolerability and health-related
quality of life (HRQoL). Participants were also asked about work days lost as a result of clinic visits.
Diary cards were collected from participants and reviewed by site staff.
A blood sample was collected at week 48 from all those who attended, and a lesion swab for later HPV
DNA detection was collected and stored if warts were present.
To reduce the loss to follow-up rate, a small financial incentive was provided to those participants who
attended the week 16 and week 48 visits in the form of Love2shop Gift Cards (highstreetvouchers.com,
Birkenhead, UK).
METHODS
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Safety
All AEs and adverse reactions (ARs) were recorded and reported according to procedures specified in
the protocol. The severity of AEs and ARs were graded and reported using the Common Terminology
Criteria for Adverse Events (CTCAE).
Outcomes
Primary outcome
The primary outcome was a combined end point of wart clearance 16 weeks after starting treatment
and remaining wart free between weeks 16 and 48. This captured both the initial clearance efficacy
and the impact on relapse or recurrence.
Secondary outcomes
The two components of the combined primary end point were considered as factor-specific, clinically
important secondary outcomes:
l for topical treatment, the proportion that were wart free at week 16
l for vaccination, the proportion that remained wart free between weeks 16 and 48 in those with
wart clearance at week 16.
There were a number of other secondary outcomes specified in the protocol:
l proportion that were wart free at the end of the assigned treatment course (4 or 16 weeks)
l proportion that were wart free at the end of the assigned treatment course (4 or 16 weeks) without
receiving additional treatment
l quantity of additional treatment (e.g. number of cryotherapy applications) required to achieve
clearance by week 16
l proportion that were wart free at week 16 without receiving additional treatment
l proportion that experienced complete wart clearance at any time, up to week 48
l proportion that experienced wart recurrence or relapse after complete wart clearance
l time to complete first wart clearance
l time from complete wart clearance to recurrence or relapse
l AEs
l HRQoL as measured by the EQ-5D-5L
l symptom scores
l cost of treatment including prescribed agents and clinic visits.
Sample size
The trial was originally designed with a sample size of 1000 participants with equal numbers
randomised to each of the two topical treatment arms, and each of the two vaccine or placebo
groups, in a 2 × 2 factorial design. After allowing for 20% loss to follow-up, 800 participants would
contribute primary outcome data. The anticipated proportion achieving the primary end point in the
less favourable topical treatment group was estimated at 35%, assuming a wart clearance rate of 50%
within 16 weeks and a subsequent recurrence rate of 30%. This sample size would have provided 80%
power (at the 5% significance level) to detect an increase to 45% achieving the primary end point with
the better treatment. It would also have provided 80% power to detect an increase from 35% to 45%
in the primary end point as a result of an effect of vaccination, as would arise if vaccination reduced
the recurrence rate from 30% to 10% while leaving the wart clearance rate unchanged at 50%.
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Owing to a lack of feasibility to achieve the proposed recruitment target of 1000 participants, a revised
sample size of 500 participants was proposed to the funder in February 2016.With 15% loss to follow-up,
this would now provide 52% power (at the 5% significance level) to detect the prespecified difference in
the combined primary end point. Even with a reduction in the loss to follow-up rate, which would, in itself,
be challenging, the study would be substantially underpowered for its combined primary end point.
The statistical power for the components of the primary end point were therefore also evaluated.
It was expected that the main effect of the topical treatment would be on wart clearance and the
main effect of vaccination would be on wart recurrence. The power of the study to detect a clinically
important difference in each of these secondary outcomes was calculated for the proposed reduced
trial size.
The reduced sample size would provide 80% power at the 5% significance level, assuming 15% loss to
follow-up, to evaluate each of the two components of the primary outcome: the proportion wart free at
week 16 and the proportion of those who were wart free at week 16 remaining wart free at week 48.
For the week 16 topical treatment outcome, a difference of 14% in wart clearance (57% wart clearance
in the imiquimod group vs. 43% wart clearance in the podophyllotoxin group) could be detected. For the
week 48 vaccine outcome, a difference of 16% in recurrence (12% recurrence in the vaccine group vs.
28% recurrence in the placebo group) could be detected. These differences were considered to be
clinically important and sufficient to be likely to influence management guidelines. A 5% significance
level was still used for these calculations, as there was a different outcome for each of the two factors,
to answer two independent questions.
Data collection and management
Data were entered at the Comprehensive Clinical Trials Unit (CCTU) into a MACRO v4.0 (Elsevier,
Amsterdam, the Netherlands) database, which incorporated validation checks to improve data quality.
Data verification, consistency and range checks were performed during data entry, as were checks
for missing data. Data queries were resolved by site staff before database lock and final analysis.
Additional data checks were performed when the data sets for analysis were constructed before the
final statistical analysis commenced. All variables were examined for unusual, outlying, unlabelled or
inconsistent values.
Statistical methods
All analyses were conducted on a modified intention-to-treat (ITT) basis.We included all consented
randomised participants for whom at least one follow-up visit was available regardless of their adherence
to treatment because the HIPvac [Human papillomavirus infection: a randomised controlled trial of
Imiquimod cream (5%) versus Podophyllotoxin cream (0.15%), in combination with quadrivalent human
papillomavirus or control vaccination in the treatment and prevention of recurrence of anogenital warts]
trial was a pragmatic study concerned with the clinical effectiveness and cost-effectiveness of topical
therapy with or without the addition of qHPV vaccination.
All CIs are 95% and two sided. Statistical tests used a two-sided p-value of 0.05 unless otherwise
specified. The analysis for both factors (PDX vs. IMIQ and qHPV vaccine vs. placebo) was based on
comparisons at the margins of the 2 × 2 table, such that all participants randomised to PDX were
compared with all participants randomised to IMIQ, and all participants randomised to qHPV vaccine
were compared with all participants randomised to the placebo injection.
We did not anticipate a substantial interaction between topical treatment and vaccination. However,
as a secondary analysis, we performed a prespecified interaction test between the two factors,
METHODS
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and present results from a four-arm analysis (in which each of the four treatment combinations is
regarded as a separate treatment arm), as recommended for factorial trials.
We adjusted the analyses for the stratification variables HIV status, gender and whether or not the
participant had had a previous episode of warts by including them as fixed-effect covariates. Trial site
was included in the mixed-effects models as a random effect (random intercept) to account for any
possible variation by site. Treatment effects were then estimated, conditional on HIV status, gender
and previous occurrence of warts, and account for variation between sites.
In a pragmatic clinical trial over a 48-week time frame, some patients are inevitably lost to follow-up.
Outcomes for such patients are, therefore, only partially observed. This can lead to a loss of power,
biased estimates and standard errors, and a loss of efficiency. To reduce the potential impact of bias,
and to maximise the power to detect a treatment effect, multiple imputation by chained equations42
was used to impute data from missing follow-up visits. Missing data were assumed to be missing at
random (MAR), conditional on all variables included in the imputation model, and so independent of
the values of the unobserved data themselves. The analyses for all primary and secondary outcomes
were performed on fully imputed data sets.
Three separate sets of imputed data were generated; in each case, enough imputed data were
generated such that the Monte Carlo error of the treatment effects estimated in the subsequent
analyses was minimised. Each of the three multiple imputation sets included the following as (fully
observed) explanatory variables in the imputation model: gender, HIV status, previous warts, trial site,
allocated treatment, total number of visits attended, number of additional visits attended (over and
above scheduled visits), an indicator of non-compliance and an indicator of any additional treatment
given. The first set imputed 120 sets of the week 16 wart clearance outcome, the week 48 recurrence
outcome and the outcomes wart free by week 4 and wart free by week 16. The primary outcome is a
combination of the week 16 wart clearance outcome and the week 48 wart recurrence outcome, and
was not directly imputed but determined from the imputed outcomes at weeks 16 and 48. The second
set imputed 50 sets of the outcomes wart clearance (at any time) and wart recurrence (at any time).
The final set imputed 50 sets of the quality-of-life outcomes [EuroQol-5 Dimensions (EQ-5D) health
utilities index and visual analogue scale (VAS)] at each time point.
Sensitivity analyses investigated the impact of the MAR assumption and missing data for all participants.
Changes to the protocol
The major change to the protocol was the reduction in the sample size as described in Statistical methods.
Active vaccine comparator
When funding for the trial was awarded, the design included the hepatitis A virus (HAV) vaccine as an
active comparator for the qHPV vaccine. This was to be used to ensure effective blinding of the study,
because some local reactogenicity would be expected to occur in both arms, whereas the HAV vaccine
would have no activity in treating or preventing HPV infection, unless there was any non-specific immune
stimulant effect, which was deemed to be unlikely. This design might also have helped recruitment,
because the HAV group could also derive benefit from participating, if they were not already immune to
the HAV. There is no contraindication to receiving the HAV vaccine in those who are already immune.
This design was predicated on the availability of matching the qHPV and HAV vaccines, as used in a
number of HPV vaccine efficacy studies. This methodology had to be changed when the pharmaceutical
company support for the HIPvac trial was withdrawn, and it was clear that the additional costs and
delays that this immediately imposed on the trial would be exacerbated by trying to source a matching
HAV vaccine control.
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Blinding
Without pharmaceutical company support for the trial, it was necessary to contract with an
independent pharmacy manufacturing facility to make a blinded placebo, using normal saline as the
only feasible ‘matching’ placebo. Although syringes identical to the bespoke syringes used for the
commercial stock of qHPV vaccine were procured, there were technical difficulties in filling these.
To minimise delay to the initiation of the study, an amendment that allowed non-matching placebo
syringes to be used for the first 250 participants was submitted and approved. The non-matching
syringes were of similar size but not identical in design to the qHPV vaccine. Each syringe (qHPV
vaccine or placebo) was therefore packed in an opaque plastic sleeve, and then in a plain cardboard
container, labelled with the trial details and a unique vaccine code number. Until the packaging was
opened, the allocation would remain blinded. A member of the clinical team who was not involved
in any other aspect of the assessment of the participant was instructed to open the package and
administer the vaccine, taking care to avoid unblinding any member of the research team.
Although this arrangement was intended to be temporary for the first 6 months of the trial only,
further technical problems with the filling of the matching syringes led to the decision to continue the
use of non-identical syringes for the remainder of the trial. The protocol was amended accordingly.
Inclusion of participants with HIV infection
Initially, participants known to be living with HIV were excluded on the grounds that wart treatment
and vaccine responses were reported to be impaired in this group, with implications for the sample
size. But, in December 2015, at the suggestion of the lay member of the TSC, the entry criteria were
modified to include participants living with HIV who were stable on antiretroviral treatment with a CD4
count of > 350 cells/µl and those not on antiretroviral treatment with a CD4 count of > 500 cells/µl.
This would exclude only those with more severe immunosuppression. Existing evidence indicated that
vaccine and treatment responses in the majority of patients living with HIV with a well-preserved
or restored CD4 count are not substantially different from those in patients without HIV.39–41 It was
concluded that those living with HIV and fulfilling these criteria should not be excluded. It was estimated
that 80% of participants living with HIV with warts would be eligible. It would also be of benefit to
observe if the response to the topical wart treatments and the vaccine was comparable in those with
and those without HIV, although it was acknowledged that the power to detect any such effect would
be limited. As a precaution, HIV status was added as a stratification variable. Finally, given that the
accrual to the study was behind schedule and that the prevalence of anogenital warts was higher in
those living with HIV, it was hoped that the protocol change would help the trial to meet the overall
recruitment target.
Trial oversight
A TSC was established comprising five independent members and the trial chief investigator as the only
non-independent member. Membership included a patient and public representative. The day-to-day
management of the trial was the responsibility of the University College London CCTU, with oversight
by a Trial Management Group responsible for the design, co-ordination and strategic management of
the trial and chaired by the chief investigator. An Independent Data Monitoring Committee (IDMC) was
appointed with three independent members: a clinician with expertise in HPV, a clinical triallist with
experience of HPV trials and a statistician as chairperson. All oversight committees had agreed terms
of reference.
During the course of the trial, the TSC and IDMC met together six times; the IDMC met once to
review blinded data in connection with a decision to revise the sample size. The TSC and IDMC also
made a recommendation to allow inclusion of participants living with HIV.
METHODS
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Chapter 3 Trial results
The trial was designed in 2012 and funding was confirmed in 2013. Because of issues withinvestigational medicinal product manufacture of the blinded vaccine, site activation was delayed;
the first site was opened to recruitment on 5 November 2014. Participants were recruited to the trial
between November 2014 and December 2016, with the last participant randomised in January 2017
(Figure 1) (see Appendix 1 for recruitment numbers by site). The last scheduled participant follow-up
visit was in January 2018. In all, 506 participants consented and were randomised into the trial, of
whom 503 are included in the analysis. Three participants did not start the treatment or did not attend
any follow-up and are therefore excluded from all analyses. The Consolidated Standards of Reporting
Trials (CONSORT) flow diagram summarising the recruitment and follow-up of participants in each
group is shown in Figure 2.
Baseline characteristics of participants
Of the 503 participants included in the analysis, 333 (66%) were male, 170 (34%) were female and the
median age was 31 years. A total of 410 (82%) participants were heterosexual, 67 (13%) were homosexual
and 25 (5%) were bisexual. Half of the participants (n= 251; 50%) reported one or more previous episodes
of warts. A total of 12 participants (2.4%) were HIV positive. Under one-third of participants (n = 151; 30%)
were current smokers, reporting cigarette smoking at least daily; 59 (12%) smoked cigarettes less than
daily; 118 (23%) were ex-smokers; and 173 (34%) were lifelong non-smokers Information on smoking
status was missing for just two participants (0.4%).
The complete data for participant baseline characteristics according to treatment group allocation are






































































































FIGURE 1 Recruitment graph by date of randomisation.
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• 16 – 48 weeks, n = 15
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• Excluded from analysis, n = 8
    • Did not attend baseline visit, n = 1
    • Did not attend any follow-up
        visits, n = 7
• Excluded from analysis, n = 10
    • Did not attend baseline visit, n = 1
    • Did not attend any follow-up
        visits, n = 9
• Excluded from analysis, n = 17
    • Did not attend any follow-up
        visits, n = 17
• Excluded from analysis, n = 11
    • Found to be ineligible, n = 1
    • Did not attend any follow-up
        visits, n = 10
• Not meeting inclusion criteria, n = 185
• Declined to participate, n = 385
• Other reasons, n = 45
• Started allocated intervention, n = 125
• Did not start allocated intervention
    (did not attend baseline visit), n = 1
• Started allocated intervention, n = 126
• Did not start allocated intervention
    (did not attend baseline visit), n = 1
• Started allocated intervention, n = 126 • Started allocated intervention, n = 127
















































Age (years), mean (SD) 31 (10) 31 (10) 32 (10) 30 (10)
Stratification variables
Gender, n (%)
Male 83 (66) 84 (67) 83 (66) 83 (66)
Female 42 (34) 42 (33) 43 (34) 43 (34)
Previous occurrence of warts, n (%)
No 63 (50) 63 (50) 63 (50) 63 (50)
Yes 62 (50) 63 (50) 63 (50) 63 (50)
HIV positive, n (%)
Yes 2 (2) 4 (3) 3 (2) 3 (2)
No 123 (98) 122 (97) 123 (98) 123 (98)
Quantity of warts
Diameter of largest wart (mm), median (IQR) 3 (2–5) 3 (2–5) 3 (2–5) 3 (2–5)
Total number of warts, n (%)
1–5 63 (50) 80 (63) 66 (52) 57 (45)
6–10 26 (21) 23 (18) 38 (30) 32 (25)
11–20 24 (19) 15 (12) 17 (13) 21 (17)
> 20 11 (9) 8 (6) 5 (4) 16 (13)
Missing 1 (1) 0 (0) 0 (0) 0 (0)
Position of warts, n/N (%)a
Male
Penile, shaft 48/83 (58) 45/84 (56) 41/83 (49) 52/83 (63)
Penile, glans 9/83 (11) 6/84 (7) 10/83 (12) 3/83 (4)
Penile, foreskin 15/83 (18) 16/84 (19) 15/83 (18) 20/83 (24)
Perineum 3/83 (4) 3/84 (4) 5/83 (6) 0/83 (0)
Anal/perianal 20/83 (24) 17/84 (20) 20/83 (24) 19/83 (23)
Other 22/83 (27) 25/84 (30) 28/83 (34) 20/83 (24)
Female
External genitalia 26/42 (62) 29/42 (69) 33/43 (77) 29/43 (67)
Perineum 11/42 (26) 13/42 (31) 12/23 (28) 19/43 (44)
Anal/perianal 9/42 (21) 11/42 (26) 9/43 (21) 9/43 (21)
Other 9/42 (21) 5/42 (12) 7/43 (21) 5/43 (12)
continued
DOI: 10.3310/hta24470 Health Technology Assessment 2020 Vol. 24 No. 47
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Gilson et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
15















Sexual orientation and history
Male, n (%)
Heterosexual 65 (78) 63 (75) 62 (75) 62 (75)
Homosexual 15 (18) 19 (23) 16 (19) 16 (19)
Bisexual 3 (4) 2 (2) 5 (6) 5 (6)
Other 0 (0) 0 (0) 0 (0) 0 (0)
Female, n (%)
Heterosexual 39 (93) 39 (93) 40 (93) 40 (93)
Homosexual 0 (0) 1 (2) 0 (0) 0 (0)
Bisexual 2 (5) 2 (5) 3 (7) 3 (7)
Other 1 (1) 0 (0) 0 (0) 0 (0)
Number of partners in the previous 3 months, median (IQR) 1 (1, 1) 1 (1, 2) 1 (1, 1) 1 (1, 1)
Sexual practices in the previous 3 months, n (%)a
Vaginal sex 91 (73) 81 (64) 86 (68) 92 (73)
Passive oral sex 75 (60) 73 (58) 83 (66) 78 (62)
Performed oral sex 73 (58) 77 (61) 82 (65) 77 (61)
Anal-receptive sex 12 (10) 21 (17) 17 (13) 13 (10)
Insertive anal sex 14 (11) 22 (18) 22 (17) 20 (16)
Current contraception (female), n/N (%)a
Condoms 10/43 (24) 9/42 (21) 15/43 (35) 12/42 (29)
Hormonal contraception (e.g. pill, IUS, implant, injection) 20/42 (48) 21/42 (50) 16/43 (37) 22/42 (52)
Not sexually active 4/42 (10) 4/42 (10) 5/43 (12) 2/42 (5)
Other 7/42 (17) 6/42 (14) 6/43 (14) 3/42 (7)
None 1/42 (2) 2/42 (5) 0/43 (0) 1/42 (2)
N/A (not of child-bearing potential) 0/42 (0) 0/42 (0) 1/43 (2) 2/42 (5)
Health history
Had previous episode(s) of warts, n (%) 65 (52) 68 (54) 63 (50) 64 (51)
Had previous treatment for warts (in those with a previous
episode), n/N (%)
64/65 (98) 67/68 (99) 63/63 (100) 62/64 (97)
Wart treatment for most recent episode, n/N (%)a
PDX 18/64 (28) 16/67 (24) 14/63 (22) 17/61 (28)
IMIQ 18/64 (28) 13/67 (19) 16/63 (25) 12/61 (20)
Cryotherapy 48/64 (75) 47/67 (70) 43/63 (68) 42/62 (68)
Surgery 2/64 (3) 2/67 (3) 6/63 (3) 1/62 (2)
Other 1/64 (2) 3/67 (4) 1/63 (2) 4/62 (6)
Previous bivalent HPV vaccine, n (%)
Yes 10 (8) 12 (10) 8 (6) 13 (10)
No 115 (92) 114 (90) 118 (94) 110 (87)
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Adherence to treatment and receipt of additional treatment
Over the 48-week duration of the study, 34 (15%) participants required a switch in topical treatment
from IMIQ and 41 (18%) from PDX. Only four switches in topical treatment occurred before the end of
the licensed duration of the allocated treatment (4 weeks for PDX and 16 weeks for IMIQ). A total of
139 out of 227 (61%) participants allocated to IMIQ and 29 out of 233 (12%) participants allocated to
PDX completed less than the licensed duration of each topical treatment. A total of 167 out of 233
(72%) participants allocated to PDX extended their topical treatment beyond 4 weeks (the denominator
is the number of participants who attended at least one follow-up visit).















Number of doses of vaccine in those previously
vaccinated, median (IQR)
3 (3–3) 3 (2–3) 3 (3–3) 3 (3–3)
Previous STI excluding anogenital warts, n (%)
Yes 41 (33) 43 (34) 40 (32) 44 (35)
No 82 (67) 82 (65) 86 (68) 82 (65)
Type of STI, n/N (%)a
Chlamydia 24/41 (59) 25/43 (58) 24/40 (60) 28/44 (64)
Gonorrhoea 11/41 (27) 15/43 (36) 7/40 (18) 11/44 (25)
Syphilis 2/41 (5) 2/43 (5) 2/40 (5) 1/44 (2)
Herpes 13/41 (32) 7/43 (16) 9/40 (23) 8/44 (18)
Other 7/41 (17) 8/43 (19) 7/40 (18) 9/44 (20)
Number of STI episodes, median (IQR) 0 (0–1) 0 (0–1) 0 (0–1) 0 (0–1)
Smoking, n (%)
Daily 42 (34) 33 (26) 36 (29) 40 (32)
Less than daily 13 (10) 15 (12) 10 (8) 21 (17)
Ex-smoker 32 (26) 27 (21) 34 (27) 25 (20)
Never smoked 37 (30) 50 (40) 46 (37) 40 (32)
Missing 1 (1) 1 (1) 0 (0) 0 (0)
Quality of life
EQ-5D-5L: health utility
n 110 116 119 112
Mean (SD) 0.94 (0.11) 0.92 (0.13) 0.94 (0.10) 0.92 (0.10)
EQ-5D-5L: VAS
n 111 115 119 110
Mean (SD) 83 (12) 82 (13) 82 (14) 82 (15)
IQR, interquartile range; IUS, intrauterine system; N/A, not applicable; SD, standard deviation.
a Participants may be included in more than one category.
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Over half of participants (54%) received cryotherapy treatment at any time during the study. The use
of cryotherapy was very similar, overall, between the groups: 117 out of 227 (52%) participants in the
IMIQ group and 130 out of 233 (56%) in the PDX group; and 118 out of 235 (50%) and 129 out of
225 (57%) in the qHPV and placebo groups, respectively.
Cryotherapy prior to week 16 of the study was administered to 76 out of 460 (17%) participants:
27 out of 227 (12%) in the IMIQ group and 49 out of 233 (21%) in the PDX group. Cryotherapy use
occurred earlier in the PDX group, probably owing to the shorter licensed duration of this treatment.
Complete data on participants’ adherence to the allocated treatments, switching of topical treatment
and use of additional cryotherapy is shown in Table 2.













Number randomised 125 126 126 126 251 252
Number analysed (attended at least one
follow-up visit)
118 117 109 116 227 233
Topical treatment, n (%)
Switched treatment at any time, yes 15 (13) 15 (13) 19 (17) 26 (22) 34 (15) 41 (18)
Timing of first treatment switch
Before 4 weeks 2 (2) 0 (0) 0 (0) 2 (2) 2 (1) 2 (1)
Between 4 and 16 weeks 1 (1) 3 (3) 4 (4) 4 (3) 5 (2) 7 (3)
After 16 weeks 12 (10) 12 (10) 15 (14) 20 (17) 27 (12) 32 (14)
Completed less than maximum licensed
duration of topical treatment
71 (60) 13 (11) 68 (62) 16 (14) 139 (61) 29 (12)
Extended PDX beyond 4 weeks 87 (74) 80 (69) 167 (72)
Any cryotherapy received 56 (47) 62 (53) 61 (56) 68 (59) 117 (52) 130 (56)
Timing of first cryotherapy
Before 4 weeks 0 (0) 1 (1) 1 (1) 2 (2) 1 (0.5) 3 (1)
Between 4 and 16 weeks 17 (14) 24 (21) 9 (8) 22 (19) 26 (11) 46 (20)
After 16 weeks 39 (33) 37 (32) 51 (47) 44 (38) 90 (40) 81 (35)
Has the patient had any other treatment
at their treatment centre other than
cryotherapy at any time
5 (4) 4 (3) 4 (4) 9 (8) 9 (4) 13 (6)
Has the patient had any treatment
from a source outside their treatment
centre
5 (4) 5 (4) 5 (5) 6 (5) 10 (4) 11 (5)
Vaccine, n (%)
Number of vaccine doses given
0 1 (1) 0 (0) 0 (0) 0 (0) 1 (0.4) 0 (0)
1 11 (9) 13 (11) 7 (6) 15 (13) 18 (8) 28 (12)
2 17 (14) 15 (11) 11 (10) 13 (11) 28 (12) 28 (12)
3 89 (75) 89 (76) 91 (83) 88 (76) 180 (79) 177 (76)
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Primary outcome
The primary outcome of the study was a combination of being wart free at 16 weeks and remaining
wart free at 48 weeks from the start of treatment. This was achieved in 35 out of 101 (35%) participants
allocated to receive IMIQ plus the qHPV vaccine, 38 out of 99 (38%) of those allocated to receive PDX
plus the qHPV vaccine, 25 out of 98 (26%) of those allocated to IMIQ plus the placebo vaccine and
30 out of 99 (30%) of those allocated to PDX plus placebo. The denominator in each group is those
participants who provided follow-up data at week 48.
Adjusted odds ratios (aORs) were calculated to estimate the topical treatment and vaccine effects after
adjustment for gender, previous wart recurrence and HIV status, and included imputed data for those
with missing data. The aOR for the topical treatment effect for IMIQ relative to PDX was 0.81 (95% CI
0.54 to 1.23). The aOR for the effect of vaccine relative to placebo was 1.46 (95% CI 0.97 to 2.20).
The data for the primary outcome are shown in Table 3.
Secondary outcomes
Clinically important secondary outcomes
Clinically important secondary outcomes were defined as (1) the proportion of participants who were
wart free at week 16 (of those not lost to follow-up by this time point) and (2) the proportion of
participants remaining wart free at week 48 (of those who had achieved clearance at 16 weeks and were
followed up until week 48). To estimate the topical treatment and vaccine effects for each outcome,
aORs were calculated and included imputed data for missing follow-up visits.
The proportion of participants who were wart free at week 16 was 58 out of 104 (56%) of those
allocated to IMIQ plus qHPV vaccine, 70 out of 105 (67%) of those allocated to PDX plus qHPV
vaccine, 56 out of 103 (54%) of those allocated to IMIQ plus placebo vaccine and 57 out of 102 (56%)
of those allocated to PDX plus placebo. The aOR for the topical treatment effect for IMIQ relative to
PDX was 0.77 (95% CI 0.52 to 1.14). The aOR for the effect of vaccine relative to placebo was 1.30
(95% CI 0.89 to 1.91).
TABLE 3 Primary outcome data showing participants who were wart free at week 16 and remained wart free at
48 weeks according to treatment group allocation
Outcome



















Wart free at week 16 and
remaining wart free between
weeks 16 and 48d




a Adjusted odds ratios include imputed data for missing follow-up visits.
b Odds ratios for the topical treatment effect use PDX as the reference group.
c Odds ratios for the vaccine treatment effect use placebo as the reference group.
d Denominator is number of participants not lost to follow-up at week 48.
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The proportion of participants remaining wart free at week 48 of those with clearance at week 16 was
35 out of 43 (81%) of those allocated to IMIQ plus qHPV vaccine, 38 out of 53 (72%) of those allocated
to PDX plus qHPV vaccine, 25 out of 39 (74%) of those allocated to IMIQ plus placebo vaccine and
30 out of 42 (71%) of those allocated to PDX plus placebo. The aOR for the topical treatment effect
for IMIQ relative to PDX was 0.98 (95% CI 0.54 to 1.78). The aOR for the effect of vaccine relative to
placebo was 1.39 (95% CI 0.73 to 2.63). The data for the clinically important secondary outcomes are
shown in Table 4.
Other secondary outcomes measuring treatment effectiveness
Other secondary outcomes that measured treatment effectiveness were (1) the proportion of
participants who were wart free at the end of the licensed duration of their assigned topical treatment
(4 weeks for PDX and 16 weeks for IMIQ), (2) the proportion of participants wart free at any time
during the 48-week trial period, (3) the proportion of participants who experienced wart recurrence
after achieving complete clearance, (4) the proportion of participants who were wart free at week 16
without additional procedures (cryotherapy or surgery), (5) the proportion of participants who were
wart free at the end of the licensed duration of their assigned topical treatment without additional
procedures (cryotherapy or surgery), (6) the time to complete wart clearance (days) and (7) the time
from complete wart clearance to recurrence (days). To estimate the topical treatment and vaccine
effects for binary or ordinal outcomes, aORs were calculated and included imputed data for missing
follow-up visits. Hazard ratios were calculated for time to event data (outcomes 6 and 7).
The results for the secondary outcomes measuring treatment effectiveness are shown in Table 5.
Kaplan–Meier survival estimates for time to wart clearance and recurrence are shown in Figures 3 and 4.
Adverse events
There were no serious adverse events (SAEs) of grade 4 severity in any of the groups. There were 21 SAEs
of grade 3 severity, eight of which occurred in participants allocated to IMIQ plus qHPV vaccine, four in
participants allocated to PDX plus qHPV vaccine, three in participants allocated to IMIQ plus placebo
vaccine and six in participants allocated to PDX plus placebo vaccine. Of the eight SAEs in the IMIQ plus
qHPV vaccine group, six occurred in a single participant and all eight were judged to be unrelated to either
the topical treatment or vaccine by the local investigator. Of the four SAEs in the PDX plus qHPV vaccine
group, three were judged to be unrelated to either the vaccine or placebo and one was judged unlikely to
be related to vaccine and unrelated to topical treatment. Of the three SAEs in the IMIQ plus placebo
TABLE 4 Clinically important secondary outcome data showing (1) the proportion of participants wart free at week 16
(of those not lost to follow-up) and (2) the proportion of participants remaining wart free at week 48 after clearance at
week 16 (of those not lost to follow-up)
Outcome























Remaining wart free at week 48
after clearance at week 16e




a Adjusted odds ratios include imputed data for missing follow-up visits.
b Odds ratios for the topical treatment effect use PDX as the reference group.
c Odds ratios for the vaccine treatment effect use placebo as the reference group.
d The denominator is participants not lost to follow-up at this time point.
e The denominator is participants wart free at week 16 and not lost to follow-up at week 48.
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vaccine group, all three were judged to be unrelated to either topical treatment or vaccine. Of the six SAEs
in the PDX plus placebo group, two were in a single participant; four were judged to be unrelated to either
topical treatment or vaccine, one was judged unlikely to be related to both topical treatment and vaccine
and one was judged unlikely to be related to topical treatment and unrelated to vaccine.
There was one serious adverse reaction to the topical treatment, of grade 3 severity (skin ulceration).
This occurred in a patient in the IMIQ plus qHPV vaccine group and was judged to be definitely
related to topical treatment.





















Wart free at the end of the
assigned treatment course
(4 or 16 weeks), n/N (%)d





complete wart clearance at
any time during the 48-week
trial period, n/N (%)e






relapse after complete wart
clearance, n/N (%)f




Wart free by week 16 without
additional treatment, n/N (%)g




Wart free at the end of the
assigned treatment period
(4 or 16 weeks) without
additional treatment, n/N (%)h




Treatment effects, adjusted hazard ratio (95% CI)a















Time from complete wart
clearance to recurrence/














a Adjusted odds ratios and hazard ratios include imputed data for missing follow-up visits.
b Odds ratios and hazard ratios for the topical treatment effect use PDX as the reference group.
c Odds ratios and hazard ratios for the vaccine treatment effect use placebo as the reference group.
d The denominator is participants not lost to follow-up at these time points.
e The denominator is participants who attended at least one follow-up visit.
f The denominator is participants who achieved wart clearance at any time during the trial period.
g The denominator is participants not lost to follow-up at this time point. Additional treatment is any treatment other
than continuation of the allocated topical treatment, including cryotherapy, other surgical intervention or other
topical treatment.
h The denominator is participants not lost to follow-up at these time points. Additional treatment is any treatment
other than continuation of the allocated topical treatment, including cryotherapy, other surgical intervention or
other topical treatment.
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There was one suspected unexpected serious adverse reaction, which occurred in the PDX plus placebo
vaccine group and was judged to be possibly related to vaccine and unrelated to topical treatment.
In addition, two pregnancies were reported (notifiable AEs), one in the PDX plus qHPV vaccine group
and one in the PDX plus placebo group.
The number of SAEs by group allocation is shown in Table 6.
For further details of the SAE reports and reasons for withdrawal, see Appendix 3, Tables 17–23.
Symptom scores of adverse effect severity from topical treatment
Participants self-rated the maximum intensity of any adverse effects from their allocated topical treatment
since their previous visit as none, mild, moderate or severe. Their symptom scores are shown in Table 7.
To estimate the topical treatment and vaccine effects on symptom scores, aORs were calculated from an
ordinal logistic regression model and included imputed data for missing follow-up visits. There were no


























IMIQ plus qHPV vaccine
PDX plus qHPV vaccine
IMIQ plus placebo
PDX  plus placebo
Treatment group





























IMIQ plus qHPV vaccine




FIGURE 3 Kaplan–Meier survival estimates for time to wart clearance.
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Treatment group, n/N (%)a
Treatment effects, aOR























Mild 38/76 (50) 40/73 (55) 30/61 (49) 41/68 (60)
Moderate 23/76 (30) 27/73 (37) 22/61 (36) 20/68 (29)
Severe 15/76 (20) 6/73 (8) 9/61 (15) 7/68 (10)




Mild 18/44 (41) 19/33 (58) 29/43 (67) 33/49 (67)
Moderate 18/44 (41) 14/33 (42) 9/43 (21) 14/49 (29)
Severe 8/44 (18) 0/33 (0) 5/43 (13) 2/49 (4)




Mild 14/25 (56) 13/20 (65) 17/31 (65) 22/31 (71)
Moderate 7/25 (28) 6/20 (30) 11/31 (35) 8/31 (26)
Severe 4/25 (16) 1/20 (5) 3/31 (10) 1/31 (3)




Mild 10/14 (71) 6/11 (55) 13/19 (68) 11/15 (73)
Moderate 2/14 (14) 4/11 (36) 4/19 (21) 4/15 (27)
Severe 2/14 (14) 1/11 (9) 2/19 (11) 0/15 (0)




Mild 7/7 (100) 5/5 (100) 4/6 (67) 1/2 (50)
Moderate 0/7 (0) 0/5 (0) 1/6 (17) 0/2 (0)
Severe 0/7 (0) 0/5 (0) 1/6 (17) 1/2 (50)
a The denominator for the proportion mild/moderate/severe is the number with any patient-reported adverse effect.
b Adjusted odds ratios include imputed data for missing follow-up visits.
c Odds ratios for the topical treatment effect use PDX as the reference group.
d Odds ratios for the vaccine treatment effect use placebo as the reference group.
TABLE 6 Numbers of reported SAEs by allocated treatment
Event
Treatment group (n)
Total (n)IMIQ plus qHPV PDX plus qHPV IMIQ plus placebo PDX plus placebo
SAE 8 4 3 6 21
SAR 1 0 0 0 1
SUSAR 0 0 0 1 1
Total 9 4 3 7 23
SAR, serious adverse reaction; SUSAR, suspected unexpected serious adverse reaction.
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Health-related quality-of-life outcomes
Heath-related quality-of-life outcome data, as measured by EQ-5D-5L health utility and VAS ratings,
are shown in Table 8.
Further analyses
A complete-case analysis (CCA) was performed for the primary outcome and clinically important
secondary outcomes without the use of imputed data (see Appendix 3, Table 24, for details of missing
data). The results are shown in Table 9 and are consistent with the main results shown in Tables 3 and 4.
The results of a four-arm analysis are presented in Table 10. Effectively, this approach considers
each treatment combination as a separate treatment arm and is an analysis that is recommended for
factorial trials. The reference group was the group allocated to receive PDX plus placebo vaccine,
so each of the other three treatment groups were compared with the reference group. The odds of
achieving the primary outcome for participants allocated to IMIQ plus qHPV vaccine is 1.18 times
(18% higher than) the odds for those allocated to PDX plus placebo (95% CI 0.66 to 2.12); the odds
of achieving the primary outcome for the other treatment groups compared with the reference group
can be interpreted in a similar way.
In addition, we fitted a model for the primary outcome that contained the two main effects (topical
treatment and vaccine) and an interaction term (Table 11). The interaction term was not significant
(p = 0.76).
TABLE 8 Mean EQ-5D-5L health utility and VAS ratings
Measure
Treatment group, mean (SD)













(n= 126) IMIQ vs. PDX qHPV vs. placebo
EQ-5D-5L: health utility
Week 4 0.95 (0.08) 0.94 (0.13) 0.94 (0.09) 0.93 (0.10)
Week 8 0.95 (0.09) 0.93 (0.14) 0.94 (0.09) 0.94 (0.10)
Week 16 0.95 (0.10) 0.92 (0.16) 0.96 (0.06) 0.95 (0.08)
Week 24 0.94 (0.14) 0.95 (0.12) 0.96 (0.08) 0.93 (0.10)
Week 48 0.94 (0.14) 0.93 (0.15) 0.95 (0.09) 0.95 (0.09)
Area under the curve: health utility
Multiple imputation
analysis
45.6 (4.71) 44.5 (6.74) 45.9 (3.05) 45.2 (3.77) 0.14 (–0.63 to 0.91)a –0.31 (–1.06 to 0.45)a
Complete-case
analysis
0.64 (–0.59 to 1.87) –0.24 (–1.48 to 1.00)
EQ-5D-5L: VAS
Week 4 85.0 (9.7) 83.2 (14.2) 82.2 (14.1) 81.2 (15.6) 1.05 (–1.55 to 3.65)a 2.14 (–0.66 to 4.94)a
Week 8 85.8 (12.0) 82.6 (13.9) 82.4 (13.5) 84.8 (13.3) –0.10 (–2.46 to 2.26)a 0.22 (–2.27 to 2.71)a
Week 16 86.1 (11.6) 83.3 (14.2) 85.6 (13.0) 85.7 (11.2) 0.39 (–2.12 to 2.90)a –0.43 (–2.80 to 1.94)a
Week 24 87.3 (12.5) 86.4 (14.5) 85.0 (15.3) 85.6 (13.5) 0.32 (–2.50 to 3.14)a 1.38 (–1.21 to 3.97)a
Week 48 88.0 (11.9) 85.2 (17.1) 84.5 (14.4) 87.8 (11.2) –0.62 (–3.04 to 1.81)a –0.26 (–2.97 to 2.45)a
AUC, area under the curve; CC, complete case; MI, multiple imputation; SD, standard deviation.
a Analysis carried out using multiply imputed data.
TRIAL RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
24
The interpretation of the interaction effect is that the topical treatment effect is no different in the
presence or absence of the qHPV vaccine.
Three subgroup analyses were specified a priori: gender (male vs. female), previous occurrence of
warts (no previous occurrence vs. one or more previous occurrences) and HIV status (HIV positive vs.
HIV negative) and performed by adding interaction terms to the model for the primary outcome for
each factor (topical treatment and vaccine). The resulting six interaction terms were tested separately
(topical treatment and gender, topical treatment and previous occurrence of warts, topical treatment
TABLE 11 Treatment effects from interaction model: primary outcome
Effect aOR (95% CI) p-value
Topical main effect (IMIQ vs. PDX for participant receiving vaccine placebo) 0.76 (0.42 to 1.36) 0.35
Vaccine main effect (qHPV vaccine vs. placebo for participants receiving PDX) 1.38 (0.78 to 2.41) 0.27
Interaction effect (IMIQ × qHPV vaccine) 1.14 (0.51 to 2.53) 0.76
TABLE 10 Four-arm analysis comparing the odds of achieving the primary outcome in each group, with the PDX plus











Participants achieving end point/
participants not lost to follow-up
at week 48 (%)
35/100 (35) 38/99 (38) 25/98 (26) 30/99 (30)
aOR of remaining wart free at
week 16 and remaining wart free








a Adjusted odds ratios include imputed data for missing follow-up visits.
TABLE 9 Complete-case analysis for primary and clinically important secondary outcomes
Outcome

















Wart free at week 16 and
remaining wart free between
week 16 and 48c








Remaining wart free at week 48
after clearance at week 16e




a Odds ratios for the topical treatment effect use PDX as the reference group.
b Odds ratios for the vaccine treatment effect use placebo as the reference group.
c The denominator is participants not lost to follow-up at week 48.
d The denominator is participants not lost to follow-up at this time point.
e The denominator is participants who were wart free at week 16 and not lost to follow-up at week 48.
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and HIV status, vaccination and gender, vaccination and previous occurrence of warts, and vaccination
and HIV status). There was no evidence of any interaction; all p-values for the interaction terms
outlined above were > 0.35. Complete data are shown in Appendix 3, Table 25.
As detailed in the statistical analysis plan, further analyses were undertaken to explore the sensitivity of
results to the MAR assumption. As the MAR assumption cannot be tested directly, imputation was
undertaken under various scenarios that might occur if the data were not MAR and to see if the results
obtained are consistent with the primary analysis.We proceeded as follows: we defined π0 as the
proportion of unobserved individuals experiencing the primary outcome (complete wart clearance at week
16 and remaining wart free at week 48); we defined π1 as the corresponding proportion in the observed
individuals; we defined θ as the odds ratio for the primary outcome for the observed individuals compared
with that for the unobserved individuals, adjusting for covariates in the analysis model.
Under the MAR assumption θ = 1, it may be reasonable to expect that those individuals who have a
good outcome (wart clearance) are less likely to attend follow-up visits (π0 > π1; therefore, θ < 1), but
π1 > π0 and θ > 1 is also plausible, although perhaps somewhat less so. We therefore generated three
sets of imputed data for the sensitivity analysis, with values of θ equal to 0.6, 0.8 and 1.25 using the
Stata® version 15 (StataCorp LP, College Station, TX, USA) impute command for a logistic model with an
offset. Each of the three sets of imputed data for the three scenarios outlined above (θ= 0.6, 0.8 and 1.25)
was generated using a logistic imputation model with the offset equal to ln(θ) and combined using Rubin’s
rules. The results were compared with those from the multiple imputation analysis performed under the
assumption of MAR and with the CCA. No substantive differences were found; the analyses were entirely
consistent with the multiple imputation analyses carried out under the MAR assumption and the CCA.
Therefore, we are confident that our primary results generated under the MAR assumption are robust to
plausible deviations from that assumption.
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Chapter 4 Economic evaluation
Introduction
In this chapter, we present the results of an economic evaluation conducted alongside the randomised
trial. We investigated the cost-effectiveness and cost–utility of the two topical treatments, as well as
the qHPV vaccine, in patients with anogenital warts.
We explored a range of scenarios in the economic evaluation, representing different design choices:
l factorial design – (1) each of the treatment arms in the 2 × 2 table; (2) qHPV vaccine versus placebo
or PDX cream versus IMIQ cream
l utility values – (1) values based on the EQ-5D-5L instrument used in the trial; (2) values based on
mapping values to the EQ-5D-3L
l trial population – (1) ITT population; (2) a population restricted to those who had never changed
from their allocated topical treatment; (3) a complete-case population based on the utility scores
l data interpolation – (1) interpolating missing data by assuming it is MAR; (2) interpolating missing
data by assuming it is missing not at random (MNAR)
l costs for health-care visits – (1) planned study visits to align with the ITT principle; (2) total number
of visits in the trial; (3) number of visits with warts present
l outcomes – (1) incremental costs per quality-adjusted life-year (QALY) gained; (2) incremental costs
per additional patient clearing warts by week 16; (3) incremental costs per avoided recurrence up to
48 weeks after starting treatment.
Methods
We performed a cost-effectiveness analysis (using the trial primary end points) and cost–utility analysis
(using QALYs) based on the recommended ITT population.43 The analysis compared the four randomisation
arms, allowing for interaction between the topical treatments and the vaccine. The analysis also compared
the topical treatment and vaccine separately, assuming no interaction and mirroring the efficacy analysis.
In addition, a per-protocol analysis (PPA) was undertaken, considering patients who had been treated with
the allocated topical treatment only (i.e. no change in allocated topical treatment over the course of the
trial), and we explored, in a CCA, the impact of missing utility values.
The analysis was defined prior to release of the final data set as an economic evaluation analysis plan.38
When possible, this economic evaluation followed the reference case of the National Institute for
Health and Care Excellence (NICE) and guidelines for economic evaluations from the Joint Committee
on Vaccination and Immunisation,44,45 as well as the recommendations of economic evaluations to be
conducted alongside clinical trials.43
In line with this national guidance,44,45 we adopted the perspective of the NHS. Because the trial
follow-up was only 48 weeks, mortality did not occur and there was close similarity of end points in all
four treatment arms; therefore, we adopted the time frame of the trial and did not discount future
costs or outcomes.
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Outcomes
We performed a cost–utility analysis of the incremental costs per QALY gained by each intervention.
We performed a full incremental analysis in which both dominated and extendedly dominated
interventions were removed.46 We also calculated the net monetary benefit (NMB), which can be
defined as the difference in the value of monetised economic benefits (health outcomes and costs
saved) in each arm, where the health outcome is expressed in monetary units using a range of
willingness-to-pay (WTP) thresholds.47,48
An additional threshold analysis was conducted to estimate the threshold price at which the qHPV
vaccine would become cost-effective should the vaccine be more effective than placebo.
In scenario analyses, we used both components of the combined primary end point of the trial as the
denominators in the cost-effectiveness analysis,43 that is the incremental costs per additional patient
clearing warts by week 16 and avoiding recurrence up to week 48 after starting treatment.
Resource use and costs
The total costs per patient consisted of the costs of the study medication (topical treatment and vaccine),
the (optional) cryotherapy and the care episodes. For the two topical treatments, we calculated costs
based on the number of applications of each treatment. For the qHPV vaccine, we considered the actual
number of administered vaccine doses, despite the fact that some patients did not receive all three doses
as planned, which is likely to reflect real-world clinical practice. If cryotherapy had been applied, we also
used the actual number of applications. The number of care episodes was estimated based on three
scenarios: (1) the planned study visits (four within 16 weeks and six within 48 weeks), (2) the actual
number of planned and additional visits and (3) the number of visits when warts were reported to be
present.We considered these three different cost values because (1) the planned study visits align well
with the ITT principle, (2) the total number of observed visits is in line with the other estimated resources
based on the trial, but is probably an overestimate of the number of clinic visits seen in clinical practice
and (3) the number of visits when warts were present may be regarded as most closely approximating
the number of visits seen in clinical practice. Note that the cost scenarios are listed in order of the total
number of visits involved (from highest to lowest), rather than in order of which scenario is deemed the
most valid or probable.
For the costs of the two topical treatments, we used the NHS Business Services Authority Drug Tariff
price [£48.60 for 12 sachets of IMIQ (50mg/g); £17.83 for 5 g of PDX cream (1.5 mg/g)].49 For the
qHPV vaccine, we obtained the NHS indicative price for Gardasil of £86.50 per dose from the British
National Formulary.50 For the costs per cryotherapy treatment round (£4.95), we took the costs from
the Quality Of Life In patients with GENital warts (QOLIGEN) observational study of anogenital wart
treatment in sexual health clinics.36 For the costs of care episodes (men, £92.80; women, £126.40),
we multiplied the number of clinic visits by the sex-specific mean costs per episode of care from the
QOLIGEN study.36 Finally, we assumed that each patient would have had one STI screen, irrespective
of treatment randomisation, which is why the costs of STI screens were not included in the costs of our
economic analysis.
The base year of the analysis was 2017/18; therefore, we inflated values to Great British pounds
(GBP) 2017/18 when appropriate.51 Similar to the procedure for natural outcomes, we separated
costs at weeks 16 and 48 to allow for separate evaluations of wart clearance by week 16 and avoided
recurrence up to week 48.
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Measurement of health-related quality of life
The HRQoL of patients was measured with the disease-generic EQ-5D-5L questionnaire,52 which
measures five dimensions of diseases at five different levels. Measurements of the EQ-5D-5L and the VAS
were collected at each study visit at weeks 0 (baseline), 4, 8, 16, 24 and 48. Utility values informed by
the EQ-5D-5L scores were calculated based on the English value set, stratified by age.53 In line with the
NICE position statement on use of the EQ-5D-5L valuation set 2017 (last updated in November 2018),54
we also calculated utility values by mapping the EQ-5D-5L data to the EuroQol-5 Dimensions, three-level
version (EQ-5D-3L), value set using the preferred mapping function of van Hout et al.55
The analysis plan suggested extrapolating the data beyond the end of the follow-up period of the
clinical trial (week 48) using suitable functions such as piecewise polynomials (also known as splines).
Based on the results of the within-trial period of 48 weeks, however, it was decided to not extrapolate
the results for HRQoL beyond the trial duration given the considerable overlap of results and
convergence of HRQoL across treatment arms (Figure 5).
The QALYs gained in each arm were estimated based on the area under the curve as a function of time
since recruitment,46 adjusted for the patient-specific baseline HRQoL.56 In addition to the mapped
EQ-5D-3L utility scores used for the base-case analysis, we also explored the EQ-5D-5L utility scores.
Missing data
Multivariate imputations by chained equations were used to impute values for the missing data of
EQ-5D utility scores using predictive mean matching and pooling estimates from 50 multiply imputed
data sets using Rubin’s rules (see Chapter 2). The data were assumed to be MAR in the base-case
analysis, but we also explored an alternative, MNAR, assumption that implied reducing the missing
values by 10% and 20%, respectively57 (see Scenario analysis).
Uncertainty analysis
We explored the uncertainty associated with the imputation and the study sample in a combined
bootstrapping approach.43 First, we bootstrapped each treatment group in the original data set that
included the missing values. Then, we imputed the missing values before estimating for each patient
the total costs and (adjusted) QALYs. Finally, we calculated the mean values for each treatment arm
and the expected NMB. We repeated this process for 500 bootstrap replicates.
We visualised the results for all four treatment arms in cost-effectiveness plots, which present the
total QALYs gained on the x-axis and the total costs incurred on the y-axis. The plots display outcomes
using both the EQ-5D-3L and EQ-5D-5L for measuring the QALY gain as well as the three cost
scenarios for care episodes to estimate the total costs per patient. Point estimates are shown in larger
size and the uncertainty estimated from the combined bootstrapping approach is shown as scatterplots
with contour overlays (see Results).
Furthermore, we used the NMB to visualise the uncertainty of the treatment arms in a cost-effectiveness
acceptability curve (CEAC), which presents the joint probability of multiple treatment options being
cost-effective in repeated iterations (see Figure 8). Given that the trial dealt with more than two treatment
options, we identified the optimal option with the highest mean NMB using the cost-effectiveness
acceptability frontier.58 This is in line with the presumed objective of the NHS of maximising health with
limited resources.44
Scenario analysis
In a scenario analysis, we performed the cost-effectiveness analysis separately for both factors (i.e. PDX
vs. IMIQ and qHPV vaccine vs. placebo), corresponding to the primary efficacy analysis, and assuming
no interaction. For this analysis, we calculated the incremental QALY gain using a multivariate linear
regression model, adjusting for the baseline covariates and HRQoL scores and using the treatment as a
dummy variable to estimate the incremental difference.56
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We also performed sensitivity analyses on the MAR assumption in which we reduced the imputed
HRQoL scores by 10% and 20% to explore the impact of the imputations on the results.57
Results
The HIPvac trial recruited a total of 503 participants whose demographic characteristics were similar
and well distributed among the four treatment arms, excluding the HIV status of patients receiving
IMIQ plus qHPV vaccine (see Table 1). For the PPA, 408 patients who did not switch to the other
cream by week 16 were included, as were 382 patients who had not switched by week 48. For the
CCA, 454 participants were included for both 16 and 48 weeks given that patients with missing utility
values typically missed a value at least once during the first 16 weeks, resulting in no different
population between week 16 and week 48. The balance of patient characteristics between treatment
arms was preserved in both analyses (see Appendix 4, Tables 26 and 27).
The factor analysis showed lower resource use at week 48 in the qHPV vaccine arms than in the placebo
arms in all three analysed populations (except for the vaccine itself; see ITT population in Table 12 and
PPA and CCA populations in Appendix 4, Tables 29 and 30).
The factor analysis for the creams is rather inconclusive and indicates slightly lower numbers of
cryotherapy sessions in the IMIQ arms, but a higher total number of study visits with warts existent
and a lower number of study visits in total (Table 12). Similar results were seen over 16 weeks and for
the PPA and CCA populations (see Appendix 4, Tables 28–30).
The costs of the different treatments reflect the pattern seen in the resource consumption. Across the
three analysed populations, the costs for the study medications, cryotherapy and vaccine generally
increased when moving from ITT to PPA, and they were similar for the ITT and CCA populations (see
Appendix 4, Tables 31–33). For the three scenarios of the study visits investigated, the costs for the
four or six scheduled visits within 16 or 48 weeks, respectively, did not change. The planned number of
study visits was always higher than the observed number of visits and than the number of visits with
warts present (Figure 6) because of failure of some participants to attend. The costs for visits when
warts were present were about two-thirds the costs of the planned visits.
The highest cost category is the cost of clinic visits (driven by the number of visits made), followed by
the vaccine costs. The least expensive cost category is cryotherapy.
TABLE 12 Resource use per patient over 48 weeks: ITT population
Resource
Meana (95% CI)
IMIQ plus qHPV PDX plus qHPV IMIQ plus placebo PDX plus placebo
IMIQ courses 2.14 (0.00 to 6.00) 0.33 (0.00 to 4.00) 2.20 (0.00 to 5.00) 0.55 (0.00 to 4.88)
PDX courses 0.15 (0.00 to 1.90) 1.55 (0.00 to 3.88) 0.18 (0.00 to 1.88) 1.61 (0.00 to 4.00)
qHPV vaccines 2.54 (1.00 to 3.00) 2.53 (1.00 to 3.00) 0.00 0.00
Cryotherapies 1.06 (0.00 to 6.80) 1.08 (0.00 to 6.88) 1.51 (0.00 to 7.00) 1.56 (0.00 to 7.88)
Study visits 5.30 (1.00 to 11.90) 5.25 (1.00 to 11.00) 5.48 (1.00 to 11.00) 5.69 (1.00 to 12.88)
Visits with warts 3.74 (1.00 to 9.00) 3.40 (1.00 to 8.88) 4.03 (1.00 to 10.00) 3.98 (1.00 to 11.62)
a Each course dispensed is sufficient for 4 weeks.
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Mean utility scores (mapped to the EQ-5D-3L) were consistently greater than 0.87 at every time point
and across all analysed populations (see Appendix 4, Table 39). The utility values generally seemed to
increase over time, although the CIs were wide.
When using the EQ-5D-5L value set to derive utility scores, all mean utility scores were slightly higher
and consistently greater than 0.92 at every time point and across all analysed populations (see
Appendix 4, Table 40). Similarly, using the EQ-5D-3L utility scores, the values generally increased over
time, but with wide CIs.
After adjusting for the different baseline utility values, the mean QALY gain over time was higher for
PDX than for IMIQ in all three analysed populations and with both EQ-5D utility scores (Table 13).
Likewise, the mean QALY gain over time was always higher for placebo than for the qHPV vaccine
(except for PDX in the PPA population). Similar results were seen when looking only at the first
16 weeks (see Appendix 4, Table 41).
Overall, it is noteworthy that the 95% CIs of the adjusted incremental QALYs were largely overlapping
between treatments, and always crossed zero.
The incremental cost-effectiveness results of all three analysed populations (ITT, PPA and CCA) point
towards PDX without qHPV vaccine being the most cost-effective intervention among the four
treatments considered, at the current list price for qHPV vaccine (£86.50 per dose) and at both week 48
(Table 14) and week 16 (see Appendix 4, Table 34). In addition, treatment with PDX plus qHPV vaccine
may be beneficial over treatment with only PDX in the ITT and PPA populations at week 48 as measured
with the EQ-5D-3L, but most pronounced in the PPA with incremental cost-effectiveness ratios
(ICERs) between £16,000/QALY and £19,000/QALY (see Table 14). Results were similar at 16 weeks
(see Appendix 4, Table 34).
With the EQ-5D-5L, PDX plus placebo dominates all other options at week 48 in all three analysed
populations excluding the PPA, which showed a positive QALY gain with the addition of the qHPV
vaccine but at ICERs of > £46,000/QALY. At week 16, PDX plus placebo dominated all other options
(see Appendix 4, Table 34).
TABLE 13 Adjusted QALY gain over 48 weeks by analysed population type and HRQoL utility measure (EQ-5D-3L vs.
EQ-5D-5L)
Measure
Adjusted QALY gain (95% CI)
IMIQ plus qHPV PDX plus qHPV IMIQ plus placebo PDX plus placebo
ITT analysis
EQ-5D-3L 0.018 (–0.187 to 0.214) 0.044 (–0.103 to 0.261) 0.034 (–0.136 to 0.243) 0.044 (–0.118 to 0.295)
EQ-5D-5L 0.011 (–0.075 to 0.137) 0.023 (–0.059 to 0.166) 0.018 (–0.087 to 0.181) 0.026 (–0.058 to 0.186)
PPA without change in allocated topical treatment
EQ-5D-3L 0.016 (–0.177 to 0.188) 0.056 (–0.144 to 0.238) 0.029 (–0.091 to 0.275) 0.044 (–0.102 to 0.284)
EQ-5D-5L 0.009 (–0.062 to 0.090) 0.030 (–0.091 to 0.174) 0.016 (–0.052 to 0.177) 0.026 (–0.060 to 0.182)
CCA
EQ-5D-3L 0.017 (–0.180 to 0.217) 0.038 (–0.105 to 0.263) 0.037 (–0.132 to 0.276) 0.043 (–0.116 to 0.292)
EQ-5D-5L 0.011 (–0.082 to 0.143) 0.021 (–0.060 to 0.165) 0.019 (–0.081 to 0.184) 0.026 (–0.056 to 0.189)
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TABLE 14 Cost-effectiveness results by analysed population: week 48
Treatment






warts existing EQ-5D-3L EQ-5D-5L EQ-5D-3L EQ-5D-5L
ITT analysis
PDX plus placebo 689 654 473 0.0437 0.0259 Reference Reference
IMIQ plus placebo 743 696 541 0.0342 0.0176 Dominated Dominated
PDX plus qHPV vaccine 892 817 627 0.0443 0.0234 380,000; 304,000;
288,000a
Dominated
IMIQ plus qHPV vaccine 956 875 714 0.0177 0.0106 Dominated Dominated
PPA without change in allocated topical treatment
PDX plus placebo 665 636 417 0.0444 0.0259 Reference Reference
IMIQ plus placebo 766 748 563 0.0294 0.0156 Dominated Dominated




IMIQ plus qHPV vaccine 973 902 717 0.0162 0.0093 Dominated Dominated
CCA
PDX plus placebo 688 648 467 0.0425 0.0256 Reference Reference
IMIQ plus placebo 737 667 512 0.0372 0.0194 Dominated Dominated
PDX plus qHPV vaccine 893 814 622 0.0383 0.0212 Dominated Dominated
IMIQ plus qHPV vaccine 960 886 718 0.0166 0.0111 Dominated Dominated
a ICERs show the incremental costs per QALY gained for all three cost scenarios: the planned study visits (four within 16 weeks and six within 48 weeks); the actual number of
planned and additional visits; the number of visits when warts were reported to be present.
Notes
The cost scenarios are listed in order of the total number of visits involved (from highest to lowest) rather than in order of which scenario is deemed the most valid or probable.






































When considering the uncertainty from both the study sampling itself and from imputation of missing
values in the sample, the reduced health gain with IMIQ was most pronounced in the group receiving
IMIQ plus the qHPV vaccine (Figure 7). Furthermore, the highest QALY gain at the lowest cost was
consistently achievable with PDX plus placebo across all the cost and utility instrument scenarios,
even when considering the uncertainty from the combined bootstrap approach (see Figure 7).
The QALY gains generally increased over time with all treatments, shifting the scatter plots to the right.
With the EQ-5D-3L, across the four treatment options, the probability of being cost-effective is the
highest and is ≥ 50% for PDX plus placebo across a range of WTP thresholds, from £0/QALY to
£50,000/QALY (Figure 8a). Similarly, the highest net benefit was always achievable with PDX plus
placebo over the WTP threshold range investigated here. PDX plus placebo vaccine is thus the
economically optimal treatment option to maximise the health gain from a limited budget when looking
at the EQ-5D-3L across all three cost scenarios (see Figure 8b). Similar results for week 16 (Figure 9)
are shown in Appendix 4.
When contrasting these results with the EQ-5D-5L, the probability of PDX plus placebo being
cost-effective increased to always > 75% (see Appendix 4, Figure 11a); it also achieves the highest
net benefit (see Appendix 4, Figure 12b), again supporting its adoption.
Threshold analysis
Given that the ICERs of the qHPV vaccine failed to be more clinically effective for the IMIQ plus qHPV
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FIGURE 7 Cost-effectiveness planes at week 48 (ITT population) contrasting the three calculated costs per study visits
with the EQ-5D-3L and EQ-5D-5L. (a) Six planned visits; (b) actually observed visits; (c) actual visits for warts. (continued )
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FIGURE 7 Cost-effectiveness planes at week 48 (ITT population) contrasting the three calculated costs per study visits
with the EQ-5D-3L and EQ-5D-5L. (a) Six planned visits; (b) actually observed visits; (c) actual visits for warts.
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FIGURE 9 Cost-effectiveness planes at week 16 (ITT population) contrasting the three calculated costs per study visits
with the EQ-5D-3L and EQ-5D-5L. (a) Six planned visits; (b) actually observed visits; (c) actual visits for warts. (continued )
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For PDX plus qHPV vaccine, positive incremental QALY gains were found ranging between 0.00015
and 0.01180 (Table 15). With incremental costs of PDX plus qHPV vaccine of always > £140 (see
Appendix 4, Tables 35 and 36), only three estimates can be rendered as being within that estimate: the
values of the EQ-5D-3L in the PPA between a threshold of £20,000/QALY and £30,000/QALY. Results
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FIGURE 9 Cost-effectiveness planes at week 16 (ITT population) contrasting the three calculated costs per study visits
with the EQ-5D-3L and EQ-5D-5L. (a) Six planned visits; (b) actually observed visits; (c) actual visits for warts.






EQ-5D-3L 0.0005 16.10 10.70 5.40
EQ-5D-5L Dominated N/A N/A N/A
PPA without change in allocated topical treatment
EQ-5D-3L 0.0118 355.00 237.00 118.00
EQ-5D-5L 0.0042 126.00 84.20 42.10
CCA
EQ-5D-3L Dominated N/A N/A N/A
EQ-5D-5L Dominated N/A N/A N/A
N/A, not applicable.
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For the vaccine, at higher incremental costs, the incremental QALYs were always negative (see Appendix 4,
Tables 43–46). By contrast, the topical treatment was always associated with positive incremental QALYs
and fewer incremental costs for PDX (see Appendix 4, Tables 43–46). Results were the same for weeks 48
and 16. For illustration, the full model is shown for the ITT for both factors in Appendix 4, Table 46).
In addition, we also included the results for the EQ-5D-5L utility scores; these were always in the same
direction as the EQ-5D-3L scores.
Cost-effectiveness per natural outcomes
Apart from the conventional cost–utility analysis, we also explored the incremental cost-effectiveness
of each option in terms of the primary clinical end points of the trial (see Chapter 3).
The most cost-effective option was, again, PDX plus placebo in both primary outcomes. For the patients
remaining wart free by week 16, further gains were achievable with PDX plus qHPV vaccine (see
Appendix 4, Table 45), with incremental costs per additional patient remaining wart free of between
£1280 and £1350 (see Appendix 4, Table 37). For the patients with avoided recurrence by week 48,
further gains in reductions were achievable with IMIQ plus placebo and IMIQ plus qHPV (see Appendix 4,
Table 38), with the incremental costs per additional patient avoiding recurrence ranging between £1400
and £2300 with IMIQ plus placebo and between £2500 and £3000 with IMIQ plus qHPV vaccine
(see Appendix 4, Table 47).
This is the only analysis in which IMIQ achieved higher health gains at higher costs (both with and
without vaccine). However, the cost-effectiveness analysis with natural outcomes as the denominator
does not allow comparisons with interventions in other disease areas (other than anogenital warts).
Thus, from the NHS perspective adopted in this analysis, the cost–utility analysis results (in terms of
costs per QALY gained) are of more policy relevance.
Missing-not-at-random assumption of missing values
The scenario analysis of the alternative MNAR assumption (see Chapter 4,Methods,Missing data) resulted
in positive mean values for all four treatment groups and for both EQ-5D valuation sets (Table 16)
(see Appendix 4, Table 24). The direction of effect is always identical for both factors. The highest QALY
gain among the four treatment options would still be seen with PDX plus placebo, except for the EQ-5D-3L




EQ-5D-3L utilities EQ-5D-5L utilities
Week 16 Week 48 Week 16 Week 48
PDX plus placebo –10 0.0262 0.0486 0.0172 0.0312
–20 0.0291 0.0536 0.0203 0.0365
IMIQ plus placebo –10 0.0165 0.0359 0.0093 0.0201
–20 0.0196 0.0398 0.0126 0.0242
PDX plus qHPV vaccine –10 0.0277 0.0473 0.0121 0.0271
–20 0.0313 0.0513 0.0159 0.0313
IMIQ plus qHPV vaccine –10 0.0030 0.0276 0.0078 0.0202
–20 0.0087 0.0347 0.0139 0.0279
Note
The treatment groups are in the same order of costs as in the base-case analysis.
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utilities over 16 weeks. Compared with the base-case analysis, the improved utility values with the addition
of the qHPV vaccine to PDX leads to higher QALY gains over 16 weeks only, not over 48 weeks. The higher
values obtained here versus the base case are largely driven by the fact that the majority of missing utility
values are missing at the beginning of the study, and reducing them by 10% or 20% thus increases the
gain over time.
At incremental costs of £203, £163 and £154 over 16 weeks (according to the three cost scenarios;
see Appendix 4, Table 36) and incremental QALY gains of 0.0015 (MNAR–10%) and 0.0022 (MNAR–20%),
the ICER would still be above conventional thresholds at £135,000, £109,000 and £103,000 per QALY
(MNAR–10%) as well as at £92,000, £74,000 £70,000 per QALY (MNAR–20%), respectively.
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The trial recruited 503 participants from 22 centres across England and Wales to address twoquestions that are relevant to the majority of patients with warts presenting to sexual health
clinics in the UK: first, the relative efficacy of the two most commonly used topical treatments and,
second, a novel question regarding the possible benefit of using the qHPV vaccine to either enhance
the clearance of warts or reduce the rate of recurrence.
The combined end point analysis included both the proportion of participants who experienced clearance
at 16 weeks after starting their allocated topical treatment and the proportion of participants who
remained wart free at the end of 48 weeks. This was chosen as the most meaningful outcome for patients.
The analysis used multiple imputation to reduce the possible effect of bias due to incomplete follow-up,
and the conclusions were very similar for the CCA. The analysis showed no significant difference between
IMIQ and PDX (aOR 0.81 in favour of PDX). The CI is wide (95%CI 0.54 to 1.26) as a consequence of the
reduction in the sample size of the trial from 1000 participants, as originally proposed, to a revised target
of 500 participants. However, the interval does suggest that IMIQ is not superior to PDX by a clinically
important degree (the upper bound is only 1.26). By the same analysis, the qHPV vaccine was compared
with placebo: the results favoured the qHPV vaccine (aOR 1.46). The CI was, again, wide, but the lower
margin of the interval was very close to 1 (95%CI 0.97 to 2.20). Furthermore, when the individual
components were analysed separately, the effect size was similar for both the week 16 clearance (aOR
1.30, 95%CI 0.89 to 1.91) and remaining wart free at week 48 (aOR 1.39, 95%CI 0.73 to 2.63). These
results are consistent with an effect of vaccine in both increasing the response to topical treatment and
reducing recurrence. However, the results are ultimately inconclusive; the CIs all include 1, indicating
uncertainty as to whether or not vaccine has any effect. The separate end point analysis of the topical
treatment showed that, although the result favoured PDX for clearance (aOR 0.77), the odds ratio was
very close to 1 for remaining wart free at week 48 (aOR 0.98, 95%CI 0.54 to 1.78). This suggests that,
with extended use for up to 16 weeks, PDX may be more effective than IMIQ used for a similar period,
but this remains uncertain. Prior evidence that IMIQ is associated with a lower recurrence rate than PDX
is not supported by this trial.
During the 7 years from the development of the proposal to the completion of this study, no other
studies were published that compared the efficacy of IMIQ and PDX, to our knowledge.59 This remains
the largest such study to date, and the first study to compare the recurrence rate in a randomised
trial, to our knowledge. There have been no studies published on the effect of vaccine as an adjunct to
treatment, or to prevent recurrence, although there are ongoing studies that may provide evidence on
recurrence (see Future research).
Trial population
This was a pragmatic trial involving as wide a range of participants as possible to ensure that the
results were generalisable to patients attending sexual health services, where 80% of patients with
genital warts are treated. Patients with a first presentation of warts, and those with a previous
episode, were included, but not those who had only recently been treated (within the previous 3 months);
the efficacy of treatment for warts that were resistant to standard treatment was not included in the
research question. A history of warts was a stratification variable and was well balanced across groups;
50% of participants had a history of warts, similar to national clinic data.
We excluded patients who had received the qHPV vaccine in the past, but not those who had received
the bivalent vaccine because this is specific to HPV types 16 and 18 and is therefore not expected
to have a measurable effect against HPV types 6 or 11. Only 9% of participants had received the
bivalent vaccine.
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Patient and public involvement
Obtaining meaningful patient and public involvement in sexual health studies has proved difficult. In
contrast with the related specialty of HIV medicine, sexual health clinic patients are transient and are
often seen in a service only once and not under long-term follow-up, although they may be repeat
attenders. Therefore, we used a patient support group linked to the HIV outpatient service at the
Mortimer Market Centre, which shares facilities with a large sexual health clinic and which was one
of the trial sites. Because many of the support group had attended the sexual health clinic as well,
their input was useful, even though very few of the study population were living with HIV. The lay
representative on the TSC was instrumental in encouraging the change in the protocol to remove the
HIV exclusion criterion, which was consistent with a general move not to exclude HIV in clinical trials
of other conditions. Since this study was initiated, a public panel has been established by the British
Association for Sexual Health and HIV that has the role of commenting on information and guidance
produced by the association. The group is available to comment on research proposals.
Interventions
Standard first-line treatment for genital warts is topical therapy or cryotherapy. Our primary interest
was the relative efficacy of PDX and IMIQ, so a no-treatment arm was not included. However, the
vaccine comparison was against placebo, because use of vaccine in this situation is not currently
approved or recommended. A vaccine-only arm would have been of interest, but more difficult to
justify: it would have increased the required size of the study, and possibly made it harder to recruit.
A cryotherapy arm, without PDX or IMIQ, could also have been included, but this comparison was
outside the remit of this study and would also have increased the required sample size.
Trial design
No change of topical treatment before week 16 was allowed, because this was the primary end point for
the topical treatment effect, even though the licensed duration of treatment differs for the two products.
The addition of cryotherapy after week 4 was permitted because this is consistent with current practice
in the UK. A failure of response after 4 weeks of PDX, the licensed duration of treatment, is a prompt to
consider an alternative treatment.We wanted to avoid this and to retain participants in their allocated
topical treatment arm up to week 16, if at all possible. Use of cryotherapy after week 4 was at the
discretion of the investigator and documented. Less than 1% (4/503) of participants used cryotherapy
before week 4. Use between weeks 4 and 16 was 14% (72/503 participants), with rather more in the
PDX arm than the IMIQ arm (20% vs. 11%, respectively). Previous studies have shown that the time to
response for IMIQ is longer than for PDX,7–15,18–25 and this is reflected in the longer licensed treatment
course.60,61 However, current practice is to allow consecutive repeat courses of PDX, provided that there
are signs of a continued response, as was observed in this trial. Nonetheless, clinicians may be more likely
to seek additional treatment with cryotherapy before 16 weeks. Extending IMIQ beyond 16 weeks, the
licensed duration for treatment, is less common; patients are more likely to be switched to an alternative
at this point.
We could have set the primary end point for clearance at 4 weeks for PDX and 16 weeks for IMIQ,
but considered that a single time point of 16 weeks for the primary analysis was more clinically relevant
and closer to standard practice. We included a comparison of the response at the end of the respective
licensed treatment durations as a secondary analysis. The results show clearly that 16 weeks of IMIQ
is more effective than 4 weeks of PDX (aOR 2.92, CI 1.75 to 4.87), although this analysis is complicated
by the difference in cryotherapy use (11% by week 16 in the IMIQ group vs. 1% by week 4 in the PDX
group). The results strongly support routine use of longer courses of PDX. If warts were still present at
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week 16, further treatment was at the discretion of the investigator but this was classed as treatment
failure for the primary analysis.
We hypothesised that the qHPV vaccine could affect wart clearance but is more likely to affect recurrence.
Nonetheless, we started the vaccine at the same time as topical treatment so that a treatment effect could
be observed and because, practically, that would be the easiest way to implement vaccination in this group
if it was shown to be beneficial. To detect an effect on recurrence, it was essential to minimise the loss to
follow-up.We collected outcome data up to week 48, covering the period when most recurrences are
seen, and given the difficulty in keeping participants engaged in such a trial.We allowed wide flexibility in
the time of follow-up visits and accepted self-reported outcomes if participants did not attend trial visits
after repeated prompting.We achieved 79% follow-up at week 48, which was close to the 80% target in
the original proposal, but below the more challenging target of 85% set after reducing the sample size.
Cost-effectiveness
In the economic evaluation, we explored the cost-effectiveness of the two topical treatments as well as
the added value of the qHPV vaccine.
Our results showed that the costs and resource use are fairly similar between the topical treatments
and there is a non-significant reduction in non-vaccine treatment costs with the qHPV vaccine,
compared with placebo. All patients had generally high HRQoL scores at baseline, so the room for
improvement in any of the trial arms was minimal, which is reflected in the mixed results between
treatment arms in our analysis. Clustering of responses on a few (very high) health states was
observed. Overall, however, CIs overlapped between treatments.
When mapping the EQ-5D-5L to the EQ-5D-3L, the slightly lower values obtained for the EQ-5D-3L
(see Appendix 4, Tables 39 and 40) are in line with what had been described previously.62 Based on
previous research, the observed smaller QALY gains with the EQ-5D-5L than with the EQ-5D-3L
(see Table 13) were to be expected as the interventions considered in HIPvac improve quality of life
without extending survival;63 our study thus supports previous findings.
With the EQ-5D-3L, the current preferred measure of the NICE (November 2018), the probability of
being cost-effective is highest, at ≥ 50%, for PDX without qHPV vaccine across £0–50,000 per QALY,
which increases to > 75% with the EQ-5D-5L. The incremental cost-effectiveness results of all three
analyses point towards PDX without the qHPV vaccine being the most cost-effective intervention
among the four treatments at current list prices. In addition, the qHPV vaccine may be beneficial over
treatment with only PDX as measured with the EQ-5D-3L, which was most pronounced in the PPA
with ICERs ≈ £23,000 per QALY (week 16) and £19,000 per QALY (week 48).
With ICERs above or near £100,000 per QALY for all but the PPAs, however, the use of the qHPV vaccine
is not cost-effective at the current vaccine price and at conventional thresholds of cost-effectiveness used
in England.With incremental costs of PDX plus qHPV vaccine of > £140, again, only three values of the
PPA measured with the EQ-5D-3L are between a threshold of £20,000–30,000 per QALY. However,
adding the qHPV vaccine to PDX could be cost-effective with the EQ-5D-3L if the price of the qHPV
vaccine is substantially reduced below its pharmacy price, which is the case for the national HPV
vaccine programmes.
The factorial cost-effectiveness analysis resulted in the vaccine always giving negative incremental
QALYs at higher incremental costs. By contrast, the topical treatments were always associated with
positive incremental QALYs, with fewer incremental costs for PDX.
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Strengths and limitations
Before the trial started, the withdrawal of support by the vaccine manufacturer required a substantial
redesign of the study. Without a no-cost supply of qHPV vaccine, and blinded placebo, we had to
purchase vaccine, and contract with a pharmacy manufacturing facility to make a placebo, and blind,
label and distribute the vaccine and placebo to sites. The sponsor had to take the financial risk of
purchasing the vaccine in advance so that it could to be blinded and repackaged. Furthermore, as the
syringe design was due to be changed, and we could purchase the current matching syringe only within
a limited time or risk having a non-matching placebo, we had to purchase sufficient vaccine for all
1000 participants at the outset.
All this resulted in substantial delays and increased the cost to services to participate. Because the cost
of vaccine was now an excess treatment cost to be borne by the sexual health service, we recovered
the cost by retaining funds from the site payments. Although the sites were reimbursed for research
costs, in practice, the excess treatment cost absorbed most of the payment. This delayed the approval
process for sites, and in some cases led to refusal to participate. Identification of potential sites also
coincided with an unprecedented period of uncertainty for sexual health services as the introduction
of new commissioning arrangements was followed by tendering-out of services and large-scale service
configurations. This exacerbated a long-standing lack of research infrastructure in sexual health
services. Overall, less than one-quarter of sites approached were confirmed and there were long delays
in site initiation and, subsequently, low recruitment rates.
An additional consequence of the loss of vaccine supplier support was that we had to abandon the
use of an active comparator. Hepatitis A vaccine has been used in some HPV vaccine studies as a
comparator,64,65 with the advantage that the local reactogenicity of the vaccine comparator helps the
maintenance of blinding against the qHPV vaccine. Saline injection would be much less likely to be
associated with a persistent local reaction, but it was still considered preferable to having no injection
in the control group. As the qHPV vaccine is supplied in a bespoke pre-filled syringe, we obtained
supplies of the same syringe from the supplier in the USA so that these could be filled and labelled to
maintain the blind. Unfortunately, securing the equipment to fill the syringes caused further delay and
the available batches of unfilled syringes were found to be faulty and failed the quality assurance
assessment after filling. Therefore, a similar but not fully matched syringe had to be used. To minimise
the risk of unblinding, the vaccine/placebo was packed in an opaque, sealed pouch contained in an
outer carton. The vaccine or placebo was administered by a health-care worker who was not involved
in participant recruitment or follow-up assessments and was under instruction to avoid showing the
vaccine syringe to either the participant or the trial team.
The study was designed with a sample size of 1000 participants. However, identifying trial sites in
the UK with the resources and infrastructure to recruit participants proved to be very difficult. To
complete the trial within timelines that could be agreed with the funder, even with two no-cost
extensions, a substantially reduced sample size had to be accepted. It was recognised that this would
mean that the trial was very likely to be underpowered for the combined primary end point. Although
disappointing, it was agreed with the funder that continuing with the trial was still worthwhile, and
justifiable on ethical grounds. The trial provided adequate power to detect a meaningful, if substantial,
effect on the two secondary end points that made up the combined primary end point, the rate of
clearance at week 16 and the rate of recurrence at week 48 in those who have cleared warts by
week 16. A proposal to the funder to change the primary end point from the single combined end
point to the two components as co-primary end points was not accepted.
There were also a number of strengths and limitations to the economic evaluation. We estimated the
resource use based on the actual numbers observed in the trial. To explore different scenarios, we
considered cost scenarios based on three different assumptions about the number of care episodes:
(1) the planned study visits align with the ITT principle, (2) the total number of observed visits is likely
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to be an overestimate compared with real-world care46 and (3) the number of visits with warts present
approximate the number of care episodes seen in clinical practice. All three cost scenarios explored
different assumptions about resource use and their order is not intended to reflect cost scenario
validity. Whereas the first scenario, of six planned study visits, explored equalising the differences seen
in the number of care visits between patients, the second scenario explored the actual resource use
during the trial, which was still protocol driven and therefore may not reflect clinical practice. The third
scenario adjusted the number of visits based on the presence of warts, but it may still be affected by
the protocol-specified visit schedule. The use of observational data may improve the estimates and
could be investigated further.
The CCA may underestimate the costs and overestimate the effects because it is usually the more
severe cases that are lost to follow-up.66 However, the CCA in this trial population showed that, in
comparison with the ITT population, the CCA population appeared to have similar costs and HRQoL.
This suggests that participants who were lost to follow-up may have been similar to the ITT population.
We did not extrapolate HRQoL outcomes beyond the trial duration given the close similarity of scores
in all four arms, which was already very high for all four treatment groups at baseline, and remained at
a high level throughout the trial. However, in line with current NICE guidance44,54 we used the EQ-5D-3L
utility scores for the economic evaluation and we compared these with the EQ-5D-5L utility scores, as
the version of EQ-5D to be used is currently under review in England.67
Future research
Given the reduction in the size of the trial, we could not reach a definitive conclusion on the efficacy
of qHPV vaccine to either enhance wart clearance with a topical agent or prevent recurrence, or both.
Evidence to date has been indirect, for example from the vaccine efficacy studies68,69 that were not
designed to address this issue. Since this trial commenced, other work has examining this question.
A study in Germany,70 commencing in 2014, planned to recruit 200 participants with previous genital
warts. All participants were treated by surgical excision, after which they received qHPV vaccine or
placebo. The primary end point was recurrence at 6 months after the end of the vaccine course; the trial
has been suspended and no results have been reported.
Another double-blind vaccine study in France71 is also investigating qHPV vaccine to prevent
recurrence. Vaccine or placebo are started 2–4 weeks after clearance of warts by any standard
treatment. The primary outcome is relapse-free survival from the first dose. The study will enrol
300 participants and started in 2017.
Since the HIPvac trial was proposed, a new topical agent has been licensed for the treatment of anogenital
warts. Marketed as Veregen® (Fougren Pharmaceuticals Inc, Melville, NY, USA) (in European countries) and
as Catephen® (Kora Healthcare, Dublin, Ireland) in the UK, it contains sinecatechins derived from green
tea leaves of the species Camellia sinensis. The active ingredient is epigallocatechin gallate (EGCG). The
mechanism of action is uncertain but various immunomodulatory and antiproliferative properties have
been proposed.72,73 EGCG is formulated as a 10% ointment; a 15% ointment preparation is available in
the USA only. The ointment is applied three times daily until complete clearance, or for up to 16 weeks.
Three double-blind placebo-controlled randomised trials have evaluated the 15% ointment,74–76 of which
two also evaluated the 10% ointment; the study by Gross et al.74 also assessed the efficacy of a 10%
cream preparation for which wart clearance was not statistically greater than placebo. The trials found
no difference in efficacy between the 10% and 15% ointment preparations. A meta-analysis of the three
studies77 concluded that both ointment preparations were efficacious relative to placebo. The reported
clearance rates of 47–59% are similar to those observed with IMIQ; however, no head-to-head RCTs
have been performed. It is unclear where this product will fit in the algorithm of wart treatment, but
comparative efficacy data should be prioritised.
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The HIPvac study, and the other vaccine studies referred to above, provide further evidence on the
question of wart recurrence. The possible effect of a vaccine as an adjuvant to topical treatment, with
or without cryotherapy, will require further investigation. The results of the HIPvac trial provide
support for conducting such work, given the potential size of the effect, and the findings of the
economic evaluation. Samples collected and archived in the HIPvac trial include wart swabs taken at
baseline and at the time of recurrence. These could be used to determine if the HPV type at the time
of recurrence is the same, and whether or not the pattern differs between vaccine and placebo groups.
Serum samples have also been stored so that the type-specific antibody responses can be correlated.
Peripheral blood mononuclear cells were due to be stored at selected trial sites but, given all the
delays and the over-riding priority to meet the recruitment target, this was not implemented.
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Chapter 6 Conclusions
The trial has provided the first high-quality evidence of the comparative efficacy and cost-effectivenessof the two most widely used topical treatments for genital warts, as well as the first randomised
trial to investigate the potential therapeutic benefit of a HPV vaccine in the management of patients
with anogenital warts. The study does not suggest that IMIQ is superior to PDX in terms of either wart
clearance or prevention of recurrence. It does, however, provide evidence that treatment with PDX
beyond the 4 weeks‘ licensed treatment duration provides additional benefit in those with warts
still present.
No benefit of vaccine when used in combination with either PDX or IMIQ to clear warts or prevent
recurrence has been shown. However, given the reduction in the size of the trial, and that the CI
includes a clinically meaningful effect, the results suggest that this does warrant further investigation.
Some relevant trials are ongoing elsewhere. From the perspective of the NHS, however, the qHPV
vaccine seems unlikely to be cost-effective at the current list price of the vaccine.
The challenges of conducting clinical trials to address important questions in sexual health services are
great, and need to be addressed if patients attending sexual health services are to benefit from the
potential to improve outcomes.
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Appendix 1 The HIPvac trial: participating sites
Site name NHS trust Principal investigator
Number of recruited
participants (n= 506)
Mortimer Market Centre Central and North West
London NHS Foundation Trust
Dr Richard Gilson 108
Yorclinic York Teaching Hospital NHS
Foundation Trust





Dr Mayura Nathan 25
Royal Sussex County
Hospital
Brighton and Sussex University
Hospitals NHS Trust
Dr Daniel Richardson 30
Birmingham Heartlands
Hospital
Heart of England NHS
Foundation Trust






Dr Gabriel Schembri 37
Southend University Hospital Southend University Hospital
NHS Foundation Trust
Dr Mohd Abu Bakar 27
Royal Liverpool Hospital Royal Liverpool and
Broadgreen University
Hospitals NHS Trust
Dr Mark Lawton 54
Royal Bournemouth Hospital Royal Bournemouth and
Christchurch Hospitals NHS
Foundation Trust
Dr Elbushra Herieka 13
James Cook University
Hospital
South Tees Hospitals NHS
Foundation Trust
Dr David Chadwick 29
Medway Maritime Hospital Medway NHS Foundation
Trust
Dr Rajesh Hembrom 12





Dr Phillip Hay 6
Royal Hallamshire Hospital Sheffield Teaching Hospitals
NHS Foundation Trust





Dr Stephen Kegg 12
Caldecot Centre, King’s
College Hospital
King’s College Hospital NHS
Foundation Trust
Dr Mannampallil Itty Samuel 19
New Croft Centre Newcastle upon Tyne Hospitals
NHS Foundation Trust
Dr Mayur Chauhan 44
Cardiff Royal Infirmary Cardiff and Vale University
Health Board
Dr Laura Cunningham 3
The Gate Clinic, Kent and
Canterbury Hospital
Kent Community Health NHS
Foundation Trust
Dr Anitha Vidhyadharan 10
The Park Centre for Sexual
Health, Weymouth
Community Hospital
Dorset County Hospital NHS
Foundation Trust





Dr Ade Apoola 12
St Mary’s Hospital Imperial College Healthcare
NHS Trust





Dr Andrew de Burgh-Thomas 15
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Give participant information sheet and go
through trial with participant
✗




Record wart treatment ✗ ✗ ✗ ✗ ✗ ✗ ✗
Review and record concomitant medication ✗ ✗ ✗ ✗ ✗ ✗ ✗
Examine and record approximate number
and location of warts/the absence of warts
✗ ✗ ✗ ✗ ✗ ✗ ✗
Symptom-directed general examination ✗
Urine pregnancy test (βhCG) (women of
child-bearing potential only)
✗ ✗a ✗a ✗a ✗a ✗a ✗a
Quality-of-life questionnaire ✗ ✗ ✗ ✗ ✗ ✗ ✗
Assessment of tolerability ✗ ✗ ✗ ✗ ✗
Assessment of AEs (and pregnancy) ✗ ✗ ✗ ✗ ✗ ✗ ✗
Assessment of treatment response and
need for additional/altered treatment
✗ ✗ ✗ ✗ ✗ ✗
Lesion swab for HPV detection (all
participants, samples to be archived)
✗ ✗
Blood sample for serum for HPV detection
(all participants, samples to be archived)
✗ ✗
Blood sample for PBMCs (subset of
120 consenting participants)
✗b ✗b ✗b ✗b ✗b
Supply trial wart treatment ✗ ✗ ✗
Supply/apply additional/alternative wart
treatment if required and as permitted in
the protocol
✗ ✗ ✗ ✗ ✗ ✗ (from week 4)
Vaccination ✗ ✗ ✗
Provide diary card for self-treatment and
self-examination record
✗ ✗ ✗ ✗ ✗
Collect/review diary card ✗ ✗ ✗ ✗ ✗ ✗
Completion/review of electronic trial
documentation
✗ ✗ ✗ ✗ ✗ ✗ ✗
βhCG, β-subunit human chorionic gonadotropin; PBMC, peripheral blood mononuclear cell.
a Pregnancy test to be completed if the participant has not adhered to using effective contraception and is being
prescribed any trial topical treatment.
b Blood samples for PBMCs should be taken only from consenting participants and at sites participating in the PBMC
substudy. The logistics of being involved in the PBMC substudy will be discussed at site feasibility and set-up stages.
Adapted from Murray et al.38 This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
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Appendix 3 Trial results: supplementary data
and analyses
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TABLE 18 Serious adverse events by allocated treatment








SAR IMIQ plus qHPV Skin ulceration Severe M Resolved Definitely
related
Unlikely
SAEa IMIQ plus qHPV Miscarriage at 20 weeks
(fetal death)
Severe H Resolved Unrelated Unrelated
SAEa IMIQ plus qHPV Uterine infection Severe H Resolved Unrelated Unrelated
SAEa IMIQ plus qHPV Uterine infection Severe H Resolved Unrelated Unrelated
SAEa IMIQ plus qHPV Uterine infection Severe H Resolved Unrelated Unrelated
SAEa IMIQ plus qHPV Rupture of infected uterine
fibroid
Severe H Resolved Unrelated Unrelated
SAEa IMIQ plus qHPV Myomectomy Severe H Resolved Unrelated Unrelated
SAE IMIQ plus qHPV Pneumothorax Severe H Resolved Unrelated Unrelated
SAE IMIQ plus qHPV Episode of psychosis Severe H Resolved Unrelated Unrelated
SAE PDX plus qHPV Pericarditis Severe H Resolved Unrelated Unlikely
SAE PDX plus qHPV Motorcycle accident Severe H Resolved Unrelated Unrelated












(IMIQ and PDX) (95% CI)
Difference in proportions
between qHPV and placebo
(95% CI)
AE 51/125 (41) 37/126 (29) 53/126 (42) 39/126 (31) 0.11 (0.03 to 0.20) –0.01 (–0.10 to 0.07)
SAE 4/125 (3)a 5/126 (4)b 3/126 (2)b 5/126 (4) –0.01 (–0.04 to 0.02) 0.01 (–0.02 to 0.04)
a Includes one patient with a serious adverse reaction.







































SAE PDX plus qHPV Injury to finger and hand then
subsequent sepsis
Severe H Resolved Unrelated Unrelated
NAE PDX plus qHPV Pregnancy N/A P Resolved N/A N/A
SAE PDX plus qHPV Occipital headache Severe H Resolved Unrelated Unrelated
SAE IMIQ plus placebo Diarrhoea Severe M Resolved Unrelated Unrelated
SAE IMIQ plus placebo Thyrotoxicosis Severe H Resolved with
sequelae
Unrelated Unrelated
SAEb IMIQ plus placebo Chest infection Severe H Resolved Unrelated Unrelated
SAEb IMIQ plus placebo Ear infection Severe H Resolved Unrelated Unrelated
SAE PDX plus placebo Anorectal infection leading to
anal fistula
Severe H Resolved with
sequalae
Unlikely Unrelated
SUSAR PDX plus placebo Gastrointestinal pain, nausea,
non-cardiac chest pain,
palpitations
Severe M Resolved Unrelated Possible
SAE PDX plus placebo Lymphadenopathy Severe H Resolved with
sequelae
Unlikely Unlikely
SAEc PDX plus placebo Unclear diagnosis; exacerbation
of coeliac disease
Severe H Resolved Unrelated Unrelated
SAEc PDX plus placebo Abdominal pain Severe H Resolved Unrelated Unrelated
SAEc PDX plus placebo Urinary retention Severe H Resolved Unrelated Unrelated
NAE PDX plus placebo Pregnancy N/A P Resolved N/A N/A
CTCAE, Common Terminology Criteria for Adverse Events; H, hospitalisation or prolongation of existing hospitalisation; M, otherwise medically significant; N/A, not applicable;
NAE, notifiable adverse event; P, pregnancy; SAR, serious adverse reaction; SUSAR, suspected unexpected serious adverse reaction.
a Occurred in the same patient.
b Occurred in the same patient.




























































































































































































































































































































































Blood and lymphatic system 2 0 2 2 6
Cardiac 0 1 0 0 1
Ear and labyrinth 0 1 0 1 2
Eye 0 2 0 1 3
Gastrointestinal 8 0 11 10 29
General disorders and administration
site conditions
11 3 10 4 28
Hepatobiliary 1 0 0 0 1
Infections and infestations 25 25 30 17 97
Injury, poisoning and procedural complications 2 5 8 4 19
Investigations 1 1 2 0 4
Metabolism and nutrition 1 1 2 0 4
Musculoskeletal and connective tissue 4 4 5 0 13
Neoplasms – benign, malignant and
unspecified (including cysts and polyps)
1 0 1 0 2
Nervous system 5 4 3 4 16
Psychiatric 1 5 4 3 13
Renal and urinary 1 0 0 1 2
Reproductive system and breast 2 2 2 1 7
Respiratory, thoracic and mediastinal 2 3 4 5 14
Skin/subcutaneous tissue 33 5 26 17 81
Vascular 0 1 0 0 1
Total 100 65 108 70 343












Dry skin 1 0 1 0 2
Erythema multiforme 1 0 0 0 1
Pain of skin 7 1 4 3 15
Pruritus 1 0 1 0 2
Rash acneiform 0 0 0 3 3
Rash maculopapular 1 0 1 0 2
Skin hypopigmentation 1 0 1 0 2
Skin ulceration 6 0 4 1 11
Skin/subcutaneous tissue – other 15 4 13 10 42
Urticaria 0 0 1 0 1
Total 33 5 26 17 81
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Anorectal infection 1 0 1 0 2
Eye infection 1 0 0 0 1
Gum infection 1 0 0 0 1
Infections and infestations – other 0 2 5 2 9
Kidney infection 0 0 0 1 1
Lip infection 0 1 0 0 1
Lung infection 1 1 0 1 3
Nail infection 0 0 0 1 1
Otitis media 0 2 1 0 3
Penile infection 2 0 0 0 2
Pharyngitis 3 0 1 1 5
Rash pustular 0 0 2 0 2
Rhinitis infection 0 0 1 0 1
Scrotal infection 0 1 0 0 1
Sinusitis 1 2 1 2 6
Skin infection 5 1 2 3 11
Tooth infection 0 1 1 0 2
Upper respiratory infection 5 10 5 1 21
Urethral infection 1 1 0 1 3
Urinary tract infection 1 1 3 2 7
Vaginal infection 1 2 5 2 10
Vulval infection 2 0 2 0 4
Total 25 25 30 17 97
TABLE 22 Reasons for withdrawal from topical treatment
Reason for withdrawal
Treatment group (n)
Total (n)IMIQ plus qHPV PDX plus qHPV IMIQ plus placebo PDX plus placebo
Non-compliance 0 0 0 1 1
Pregnancy 0 0 0 1 1
AR 6 1 2 5 14
Lost to follow-up 19 19 21 19 78
Other 1 4 1 10 16
Total 26 24 24 36 110
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TABLE 23 Reasons from withdrawal from vaccine/placebo treatment
Reason for withdrawal
Treatment group (n)
Total (n)IMIQ plus qHPV PDX plus qHPV IMIQ plus placebo PDX plus placebo
Pregnancy 0 0 0 1 1
AR 0 0 0 2 2
Lost to follow-up 19 19 22 19 79
Other 0 1 0 2 3
Total 19 20 22 24 85












Visit not attended 14 14 19 12
Visit attended 111 112 107 114
Presence of warts
Yes 99 91 93 96
No 12 21 14 18
Missing 0 0 0 0
Warts present, n/N (%)
Cream applied
Yes 97/99 90/91 92/93 91/96
No 2/99 1/91 1/93 4/96
Missing 0/99 (0) 0/91 (0) 0/93 (0) 1/96 (1)
Intensity of side effects, missing 2/97 (2) 2/90 (2) 2/92 (2) 6/91 (7)
EQ-5D, missing 14/99 (14) 13/91 (14) 10/93 (11) 20/96 (21)
Warts not present, n/N (%)
Warts seen last, missing 0/12 (0) 0/21 (0) 0/14 (0) 1/18 (6)
EQ-5D, missing 2/12 (17) 3/21 (14) 3/14 (21) 6/18 (33)
Week 8 (n)
Visit not attended 21 21 25 22
Visit attended 104 105 101 104
Presence of warts
Yes 72 74 74 77
No 32 31 27 27
Missing 0 0 0 0
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Warts present, n/N (%)
Cream applied
Yes 66/72 62/74 72/74 70/77
No 6/72 12/74 2/74 2/77
Missing 0/72 (0) 0/74 (0) 0/74 (0) 0/77 (0)
Intensity of side effects, missing 7/66 (11) 12/62 (19) 2/72 (3) 7/70 (10)
EQ-5D, missing 11/72 (15) 12/74 (16) 9/74 (12) 10/77 (13)
Warts not present, n/N (%)
Warts seen last, missing 1/32 (3) 0/31 (0) 1/27 (4) 1/27 (4)
EQ-5D, missing 10/32 (31) 6/31 (19) 2/27 (7) 1/27 (4)
Week 16 (n)
Visit not attended 35 32 37 36
Visit attended 90 94 89 90
Presence of warts
Yes 48 48 57 46
No 41 46 32 44
Missing 1 0 0 0
Warts present, n/N (%)
Cream applied
Yes 37/48 34/48 50/57 36/46
No 11/48 14/48 7/57 10/46
Missing 0/48 (0) 0/46 (0) 0/57 (0) 0/44 (0)
Intensity of side effects, missing 11/37 (30) 14/34 (41) 7/50 (14) 10/36 (27)
EQ-5D, missing 5/48 (10) 5/46 (11) 5/32 (16) 5/44 (11)
Warts not present, n/N (%)
Warts seen last, missing 1/41 (2) 0/48 (0) 1/57 (2) 0/46 (0)
EQ-5D, missing 10/41 (24) 15/48 (31) 9/57 (16) 13/46 (28)
Week 24 (n)
Visit not attended 34 32 33 34
Visit attended 91 94 93 92
Presence of warts
Yes 36 25 43 39
No 55 67 50 52
Missing 0 2 0 1
Warts present, n/N (%)
EQ-5D, missing 10/36 (27) 4/32 (13) 4/33 (12) 6/34 (18)
continued
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Warts not present, n/N (%)
Warts seen last, missing 2/55 (4) 0/67 (0) 0/50 (0) 0/52 (0)
EQ-5D, missing 10/55 (18) 10/67 (15) 8/50 (16) 8/52 (15)
Week 48 (n)
Visit not attended 46 40 45 44
Visit attended 79 86 81 58
Presence of warts
Yes 26 22 29 24
No 53 64 52 58
Missing 0 0 0 0
Warts present, n/N (%)
Intensity of side effects, missing 10/26 (38) 16/22 (72) 24/29 (83) 15/24 (63)
EQ-5D, missing 4/26 (15) 1/22 (5) 6/29 (21) 1/24 (4)
Warts not present, n/N (%)
Warts seen last, missing 0/53 (0) 1/64 (2) 0/52 (0) 1/58 (2)
EQ-5D, missing 4/53 (8) 14/64 (22) 5/52 (10) 6/58 (10)



































































HIV negative 2/5 (40) 3/7 (43) 2/6 (33) 3/6 (50)
OR, odds ratio.
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Appendix 4 Health economic analysis:
additional tables
TABLE 26 Demographic characteristics of the trial population for the PPA without change in allocated topical treatment
Characteristic
Treatment group
IMIQ plus qHPV PDX plus qHPV IMIQ plus placebo PDX plus placebo
Week 16
n 107 103 100 98
Age (years), mean (95% CI) 31.0 (19.5 to 55.5) 31.6 (20.0 to 59.5) 32.7 (20.0 to 58.6) 30.2 (19.1 to 55.9)
Gender (female = 1) 0.327 0.359 0.390 0.334
Previous warts 0.514 0.476 0.530 0.510
HIV status 0.019 0.039 0.020 0.020
Week 48
n 102 97 95 88
Age (years), mean (95% CI) 31.1 (19.5 to 55.5) 31.5 (20.0 to 59.5) 32.7 (20.0 to 58.6) 30.3 (19.1 to 55.9)
Gender (female = 1) 0.343 0.340 0.379 0.341
Previous warts 0.520 0.485 0.537 0.500
HIV status 0.010 0.031 0.021 0.023
For the PPA we included all participants who were treated with the allocated topical treatment and never received the
other, non-allocated topical cream.
TABLE 27 Demographic characteristics of the trial population for the CCA without missing utility values
Characteristic
Treatment group
IMIQ plus qHPV PDX plus qHPV IMIQ plus placebo PDX plus placebo
Week 16
n 112 110 116 116
Age (years), mean (95% CI) 30.9 (19.5 to 55.5) 31.6 (20.0 to 59.5) 31.8 (20.0 to 58.6) 30.2 (19.1 to 55.9)
Gender (female = 1) 0.348 0.336 0.328 0.345
Previous warts 0.491 0.518 0.509 0.500
HIV status 0.018 0.036 0.026 0.026
Week 48
n 112 110 116 116
Age (years), mean (95% CI) 30.9 (19.5 to 55.5) 31.6 (20.0 to 59.5) 31.8 (20.0 to 58.6) 30.2 (19.1 to 55.9)
Gender (female = 1) 0.348 0.336 0.328 0.345
Previous warts 0.491 0.518 0.509 0.500
HIV status 0.018 0.036 0.026 0.026
For the CCA population we considered participants without missing values in the utility scores.
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TABLE 28 Resource use per participant: ITT population
Time horizon
Treatment group, mean (95% CI)
IMIQ plus qHPV PDX plus qHPV IMIQ plus placebo PDX plus placebo
IMIQ (coursesa)
Week 16 1.81 (0.00 to 4.00) 0.14 (0.00 to 2.00) 1.91 (0.00 to 4.00) 0.29 (0.00 to 3.88)
Week 48 2.14 (0.00 to 6.00) 0.33 (0.00 to 4.00) 2.20 (0.00 to 5.00) 0.55 (0.00 to 4.88)
PDX (coursesa)
Week 16 0.05 (0.00 to 1.00) 1.41 (0.00 to 3.00) 0.10 (0.00 to 1.00) 1.42 (0.00 to 3.00)
Week 48 0.15 (0.00 to 1.90) 1.55 (0.00 to 3.88) 0.18 (0.00 to 1.88) 1.61 (0.00 to 4.00)
qHPV vaccine (injections)
Week 16 1.82 (1.00 to 2.00) 1.81 (1.00 to 2.00) 0.00 0.00
Week 48 2.54 (1.00 to 3.00) 2.53 (1.00 to 3.00) 0.00 0.00
Cryotherapy (applications)
Week 16 0.51 (0.00 to 2.90) 0.64 (0.00 to 2.90) 0.52 (0.00 to 3.00) 0.71 (0.00 to 3.00)
Week 48 1.06 (0.00 to 6.80) 1.08 (0.00 to 6.88) 1.51 (0.00 to 7.00) 1.56 (0.00 to 7.88)
Study visits
Week 16 3.58 (1.00 to 6.90) 3.48 (1.00 to 5.00) 3.42 (1.00 to 6.00) 3.49 (1.00 to 5.88)
Week 48 5.30 (1.00 to 11.90) 5.25 (1.00 to 11.00) 5.48 (1.00 to 11.00) 5.69 (1.00 to 12.88)
Visits with warts
Week 16 2.91 (1.00 to 5.90) 2.71 (1.00 to 5.00) 2.85 (1.00 to 5.00) 2.80 (1.00 to 5.00)
Week 48 3.74 (1.00 to 9.00) 3.40 (1.00 to 8.88) 4.03 (1.00 to 10.00) 3.98 (1.00 to 11.62)
a Each course dispensed is sufficient for 4 weeks.
TABLE 29 Resource use per participant: PPA population
Time horizon
Treatment group, mean (95% CI)
IMIQ plus qHPV PDX plus qHPV IMIQ plus placebo PDX plus placebo
IMIQ (coursesa)
Week 16 2.04 (1.0 to 4.0) 0.00 2.24 (1.0 to 4.0) 0.00
Week 48 2.31 (1.0 to 6.0) 0.00 2.58 (1.0 to 5.0) 0.00
PDX (coursesa)
Week 16 0.00 1.61 (1.0 to 3.0) 0.00 1.66 (1.0 to 3.0)
Week 48 0.00 1.72 (1.0 to 3.0) 0.00 1.86 (1.0 to 4.0)
qHPV vaccine (injections)
Week 16 1.91 (1.0 to 2.0) 1.89 (1.0 to 2.0) 0.00 0.00
Week 48 2.66 (1.0 to 3.0) 2.68 (1.0 to 3.0) 0.00 0.00
Cryotherapy (applications)
Week 16 0.52 (0.0 to 2.3) 0.73 (0.0 to 3.0) 0.56 (0.0 to 3.0) 0.79 (0.0 to 3.0)
Week 48 0.96 (0.0 to 4.5) 1.03 (0.0 to 5.0) 1.39 (0.0 to 7.0) 1.31 (0.0 to 5.0)
Study visits
Week 16 3.73 (2.0 to 6.3) 3.77 (2.0 to 5.5) 3.75 (2.0 to 6.5) 3.76 (2.0 to 6.0)
Week 48 5.36 (2.0 to 9.5) 5.47 (2.0 to 9.2) 5.82 (2.0 to 11.0) 5.74 (2.0 to 10.8)
Visits with warts
Week 16 3.00 (1.0 to 5.3) 2.86 (1.0 to 5.0) 3.04 (1.0 to 5.5) 2.88 (1.0 to 5.0)
Week 48 3.59 (1.0 to 8.0) 3.31 (1.0 to 6.6) 4.10 (1.0 to 9.6) 3.66 (1.0 to 7.8)
a Each course dispensed is sufficient for 4 weeks.
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TABLE 30 Resource use per participant: CCA population
Time
horizon
Treatment group, mean (95% CI)
IMIQ plus qHPV PDX plus qHPV IMIQ plus placebo PDX plus placebo
IMIQ (coursesa)
Week 16 1.82 (0.0 to 4.0) 0.15 (0.0 to 2.0) 1.90 (0.0 to 4.0) 0.30 (0.0 to 3.8)
Week 48 2.15 (0.0 to 6.1) 0.33 (0.0 to 3.9) 2.15 (0.0 to 5.0) 0.53 (0.0 to 4.7)
PDX (coursesa)
Week 16 0.05 (0.0 to 1.0) 1.42 (0.0 to 3.0) 0.09 (0.0 to 1.0) 1.41 (0.0 to 3.0)
Week 48 0.17 (0.0 to 1.7) 1.55 (0.0 to 3.7) 0.16 (0.0 to 1.7) 1.58 (0.0 to 4.0)
qHPV vaccine (injections)
Week 16 1.82 (1.0 to 2.0) 1.81 (1.0 to 2.0) 0.0 0.0
Week 48 2.55 (1.0 to 3.0) 2.54 (1.0 to 3.0) 0.0 0.0
Cryotherapy (applications)
Week 16 0.51 (0.0 to 2.7) 0.65 (0.0 to 3.0) 0.49 (0.0 to 2.9) 0.68 (0.0 to 3.0)
Week 48 1.11 (0.0 to 6.2) 1.11 (0.0 to 6.5) 1.41 (0.0 to 7.3) 1.58 (0.0 to 7.9)
Study visits
Week 16 3.63 (1.0 to 6.9) 3.53 (1.0 to 5.0) 3.38 (1.0 to 6.1) 3.49 (1.0 to 5.8)
Week 48 5.38 (1.0 to 11.6) 5.22 (1.0 to 10.8) 5.29 (1.0 to 11.1) 5.65 (1.0 to 12.9)
Visits with warts
Week 16 2.93 (1.0 to 5.9) 2.75 (1.0 to 5.2) 2.79 (1.0 to 5.2) 2.79 (1.0 to 5.0)
Week 48 3.77 (1.0 to 9.2) 3.35 (1.0 to 8.6) 3.84 (1.0 to 10.0) 3.94 (1.0 to 11.3)
a Each course dispensed is sufficient for 4 weeks.
TABLE 31 Costs per participant: ITT population
Time
horizon
Treatment group, cost (£) (95% CI)
IMIQ plus qHPV PDX plus qHPV IMIQ plus placebo PDX plus placebo
IMIQ
Week 16 87.90 (0.00 to 194.40) 6.94 (0.00 to 97.20) 92.60 (0.00 to 194.40) 14.30 (0.00 to 188.32)
Week 48 104.20 (0.00 to 291.60) 16.20 (0.00 to 194.00) 106.50 (0.00 to 243.00) 26.60 (0.00 to 236.90)
PDX
Week 16 0.86 (0.00 to 17.80) 25.00 (0.00 to 53.50) 1.70 (0.00 to 17.80) 25.30 (0.00 to 53.49)
Week 48 2.71 (0.00 to 33.90) 27.60 (0.00 to 69.10) 3.11 (0.00 to 33.40) 28.70 (0.00 to 71.30)
qHPV vaccine
Week 16 158.00 (86.50 to 173.00) 157.00 (86.50 to 173.00) 0.00 0.00
Week 48 219.00 (86.50 to 259.50) 219.00 (86.50 to 259.50) 0.00 0.00
Cryotherapy
Week 16 2.50 (0.00 to 14.40) 3.10 (0.00 to 14.90) 2.60 (0.00 to 14.90) 3.50 (0.00 to 14.86)
Week 48 5.30 (0.00 to 33.70) 5.40 (0.00 to 34.10) 7.50 (0.00 to 34.70) 7.70 (0.00 to 39.00)
Study visits
Week 16 368.00 (92.80 to 640.30) 363.00 (92.80 to 632.20) 360.00 (92.80 to 742.80) 364.00 (92.80 to 622.78)
Week 48 544.00 (126.40 to 1114.00) 549.00 (92.80 to 1021.00) 579.00 (92.80 to 1375.00) 591.00 (92.80 to 1368.00)
Visits with warts
Week 16 299.00 (92.80 to 551.70) 284.00 (92.80 to 616.40) 299.00 (92.80 to 632.20) 292.00 (92.80 to 505.76)
Week 48 382.00 (92.80 to 999.00) 359.00 (92.80 to 885.00) 424.00 (92.80 to 1249.00) 410.00 (92.80 to 1114.00)
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TABLE 32 Costs per participant: PPA population
Time
horizon
Treatment group, cost (£) (95% CI)
IMIQ plus qHPV PDX plus qHPV IMIQ plus placebo PDX plus placebo
IMIQ
Week 16 99.00 (48.60 to 194.40) 0.00 109.00 (48.60 to 194.40) 0.00
Week 48 112.40 (48.60 to 291.60) 0.00 125.00 (48.60 to 243.00) 0.00
PDX
Week 16 0.00 28.70 (17.80 to 53.50) 0.00 29.70 (17.80 to 53.50)
Week 48 0.00 30.70 (17.80 to 53.50) 0.00 33.20 (17.80 to 71.30)
qHPV vaccine
Week 16 165.00 (86.50 to 1730) 164.00 (86.50 to 173.00) 0.00 0.00
Week 48 230.00 (86.50 to 259.50) 232.00 (86.50 to 259.50) 0.00 0.00
Cryotherapy
Week 16 2.60 (0.00 to 11.60) 3.60 (0.00 to 14.90) 2.80 (0.00 to 14.90) 3.90 (0.00 to 14.90)
Week 48 4.80 (0.00 to 22.20) 5.10 (0.00 to 24.80) 6.90 (0.00 to 34.70) 6.50 (0.00 to 24.80)
Study visits
Week 16 384.00 (186.00 to 589.00) 393.00 (186.00 to 632.00) 400.00 (186.00 to 825.00) 390.00 (186.00 to 632.00)
Week 48 555.00 (186.00 to 906.00) 566.00 (186.00 to 978.00) 616.00 (186.00 to 1220.00) 596.00 (186.00 to 1096.00)
Visits with warts
Week 16 308.00 (92.80 to 524.00) 301.00 (92.80 to 632.20) 323.00 (92.80 to 699.00) 300.00 (92.80 to 505.80)
Week 48 370.00 (92.80 to 795.00) 345.00 (92.80 to 698.00) 431.00 (92.80 to 1138.00) 377.00 (92.80 to 989.00)
TABLE 33 Costs per participant: CCA population
Time
horizon
Treatment group, cost (£) (95% CI)
IMIQ plus qHPV PDX plus qHPV IMIQ plus placebo PDX plus placebo
IMIQ
Week 16 88.50 (0.00 to 194.40) 7.07 (0.00 to 97.20) 92.20 (0.00 to 194.40) 14.70 (0.00 to 182.40)
Week 48 104.60 (0.00 to 297.80) 15.90 (0.00 to 189.80) 104.30 (0.0 to 243.00) 25.60 (0.00 to 226.70)
PDX
Week 16 0.96 (0.00 to 17.80) 25.30 (0.00 to 53.50) 1.54 (0.00 to 17.80) 25.10 (0.00 to 53.50)
Week 48 3.03 (0.0 to 30.10) 27.70 (0.00 to 66.60) 2.92 (0.00 to 30.90) 28.10 (0.00 to 71.30)
qHPV vaccine
Week 16 158.00 (86.50 to 173.00) 157 (86.50 to 173.00) 0.00 0.00
Week 48 219.00 (86.50 to 259.50) 219 (86.50 to 259.50) 0.00 0.00
Cryotherapy
Week 16 2.50 (0.00 to 13.30) 3.20 (0.00 to 14.60) 2.40 (0.00 to 14.50) 3.40 (0.00 to 14.90)
Week 48 5.30 (0.00 to 30.90) 5.10 (0.00 to 32.10) 6.70 (0.00 to 36.10) 7.60 (0.00 to 39.20)
Study visits
Week 16 374.00 (92.80 to 643.20) 368.00 (92.80 to 632.20) 353.00 (92.80 to 757.80) 363.00 (92.80 to 617.30)
Week 48 553.00 (126.40 to 1113.00) 546.00 (92.80 to 1032.00) 553.00 (92.80 to 13630.00) 587.00 (92.80 to 1342.00)
Visits with warts
Week 16 301.00 (92.80 to 559.00) 289.00 (92.80 to 590.60) 290 (92.80 to 640.80) 291.00 (92.80 to 505.80)
Week 48 385.00 (92.80 to 961.00) 354.00 (92.80 to 890.00) 398 (92.80 to 1226.00) 406.00 (92.80 to 11150.00)
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TABLE 34 Cost-effectiveness results per analysis type: week 16
Treatment






warts present EQ-5D-3L EQ-5D-5L EQ-5D-3L EQ-5D-5L
ITT analysis
PDX plus placebo 460 407 335 0.0235 0.0144 Reference Reference
IMIQ plus placebo 514 457 395 0.0151 0.0073 Dominated Dominated




IMIQ plus qHPV 665 617 548 –0.0059 –0.0002 Dominated Dominated
PPA without change in allocated topical treatment
PDX plus placebo 450 424 333 0.0225 0.0138 Reference Reference
IMIQ plus placebo 535 511 434 0.0150 0.0068 Dominated Dominated




IMIQ plus qHPV 682 651 574 –0.0084 –0.0011 Dominated Dominated
CCA
PDX plus placebo 461 407 334 0.0202 0.0138 Reference Reference
IMIQ plus placebo 511 449 386 0.0188 0.0093 Dominated Dominated




IMIQ plus qHPV 668 624 550 –0.0074 0.0004 Dominated Dominated
a ICERs show the incremental costs per QALY gained for all three cost scenarios: the planned study visits (four within
16 weeks and six within 48 weeks); the actual number of planned and additional visits; the number of visits when
warts were reported to be present.
Incrementally calculated values are not shown as an intermediate step here but in Table 35.
Cost scenarios are listed in order of the total number of visits involved (from highest to lowest) rather than in order of
which scenario is deemed the most valid or likely. ICERs show the incremental costs per QALY gained for all three cost
scenarios, respectively.
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warts present EQ-5D-3L EQ-5D-5L EQ-5D-3L EQ-5D-5L
ITT analysis
PDX plus placebo 0 0 0 0 0 Reference Reference




PPA without change in allocated topical treatment
PDX plus placebo 0 0 0 0 0 Reference Reference






a ICERs show the incremental costs per QALY gained for all three cost scenarios: the planned study visits (four within
16 weeks and six within 48 weeks); the actual number of planned and additional visits; the number of visits when
warts were reported to be present.
No incremental results shown for the CCA analyses given that the least expensive reference case (i.e. PDX plus
placebo) achieved the highest total QALYs, dominating all other options in this study.










warts present EQ-5D-3L EQ-5D-5L EQ-5D-3L EQ-5D-5L
ITT analysis
PDX plus placebo 0 0 0 0 0 Reference Reference




PPA without change in allocated topical treatment
PDX plus placebo 0 0 0 0 0 Reference Reference





PDX plus placebo 0 0 0 0 0 Reference Reference




a ICERs show the incremental costs per QALY gained for all three cost scenarios: the planned study visits (four within
16 weeks and six within 48 weeks); the actual number of planned and additional visits; the number of visits when
warts were reported to be present.
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TABLE 39 The EQ-5D-3L (utility) scores by analysed population
Analysis
Treatment group, score (95% CI)
IMIQ plus qHPV PDX plus qHPV IMIQ plus placebo PDX plus placebo
ITT analysis
Baseline 0.911 (0.56 to 1.0) 0.879 (0.51 to 1.0) 0.895 (0.59 to 1.0) 0.877 (0.44 to 1.0)
Week 4 0.901 (0.52 to 1.0) 0.906 (0.53 to 1.0) 0.903 (0.64 to 1.0) 0.894 (0.58 to 1.0)
Week 8 0.896 (0.35 to 1.0) 0.908 (0.56 to 1.0) 0.912 (0.63 to 1.0) 0.902 (0.62 to 1.0)
Week 16 0.919 (0.51 to 1.0) 0.908 (0.57 to 1.0) 0.922 (0.69 to 1.0) 0.917 (0.64 to 1.0)
Week 24 0.927 (0.52 to 1.0) 0.915 (0.63 to 1.0) 0.927 (0.69 to 1.0) 0.917 (0.53 to 1.0)
Week 48 0.965 (0.71 to 1.0) 0.964 (0.69 to 1.0) 0.960 (0.73 to 1.0) 0.954 (0.63 to 1.0)
PPA without change in allocated topical treatment
Baseline 0.914 (0.61 to 1.0) 0.879 (0.45 to 1.0) 0.896 (0.60 to 1.0) 0.892 (0.60 to 1.0)
Week 4 0.905 (0.54 to 1.0) 0.917 (0.54 to 1.0) 0.908 (0.67 to 1.0) 0.910 (0.69 to 1.0)
Week 8 0.899 (0.38 to 1.0) 0.920 (0.57 to 1.0) 0.916 (0.65 to 1.0) 0.920 (0.67 to 1.0)
Week 16 0.922 (0.51 to 1.0) 0.916 (0.60 to 1.0) 0.921 (0.69 to 1.0) 0.934 (0.70 to 1.0)
Week 24 0.930 (0.52 to 1.0) 0.934 (0.70 to 1.0) 0.918 (0.63 to 1.0) 0.941 (0.72 to 1.0)
Week 48 0.962 (0.67 to 1.0) 0.972 (0.76 to 1.0) 0.956 (0.74 to 1.0) 0.958 (0.75 to 1.0)
CCA
Baseline 0.905 (0.56 to 1.0) 0.884 (0.55 to 1.0) 0.890 (0.49 to 1.0) 0.877 (0.45 to 1.0)
Week 4 0.899 (0.53 to 1.0) 0.906 (0.64 to 1.0) 0.899 (0.53 to 1.0) 0.886 (0.59 to 1.0)
Week 8 0.886 (0.37 to 1.0) 0.908 (0.64 to 1.0) 0.908 (0.56 to 1.0) 0.901 (0.60 to 1.0)
Week 16 0.912 (0.52 to 1.0) 0.910 (0.69 to 1.0) 0.918 (0.56 to 1.0) 0.917 (0.64 to 1.0)
Week 24 0.921 (0.54 to 1.0) 0.913 (0.68 to 1.0) 0.924 (0.63 to 1.0) 0.917 (0.54 to 1.0)
Week 48 0.961 (0.70 to 1.0) 0.963 (0.73 to 1.0) 0.956 (0.69 to 1.0) 0.955 (0.65 to 1.0)













PDX plus placebo 0 0 0 0 Reference
IMIQ plus placebo 54 42 68 0.03 1800; 1400; 2270a
IMIQ plus qHPV 213 179 173 0.07 3040; 2560; 2470a
a ICERs show the incremental costs per QALY gained for all three cost scenarios: the planned study visits (four within
16 weeks and six within 48 weeks); the actual number of planned and additional visits; the number of visits when
warts were reported to be present.













PDX plus placebo 0 0 0 0 Reference
PDX plus qHPV 147 148 141 0.11 1340; 1350; 1280a
a ICERs show the incremental costs per QALY gained for all three cost scenarios: the planned study visits (four within
16 weeks and six within 48 weeks); the actual number of planned and additional visits; the number of visits when
warts were reported to be present.
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TABLE 40 The EQ-5D-5L (utility) scores by analysed population
Analysis
Treatment group, score (95% CI)
IMIQ plus qHPV PDX plus qHPV IMIQ plus placebo PDX plus placebo
ITT analysis
Baseline 0.942 (0.70 to 1.0) 0.922 (0.62 to 1.0) 0.938 (0.63 to 1.0) 0.926 (0.66 to 1.0)
Week 4 0.939 (0.66 to 1.0) 0.932 (0.49 to 1.0) 0.943 (0.75 to 1.0) 0.935 (0.70 to 1.0)
Week 8 0.938 (0.64 to 1.0) 0.930 (0.52 to 1.0) 0.946 (0.72 to 1.0) 0.942 (0.75 to 1.0)
Week 16 0.948 (0.65 to 1.0) 0.935 (0.61 to 1.0) 0.950 (0.78 to 1.0) 0.950 (0.73 to 1.0)
Week 24 0.948 (0.61 to 1.0) 0.942 (0.68 to 1.0) 0.952 (0.76 to 1.0) 0.948 (0.66 to 1.0)
Week 48 0.974 (0.84 to 1.0) 0.974 (0.76 to 1.0) 0.976 (0.84 to 1.0) 0.972 (0.74 to 1.0)
PPA without change in allocated topical treatment
Baseline 0.945 (0.73 to 1.0) 0.923 (0.62 to 1.0) 0.938 (0.63 to 1.0) 0.935 (0.73 to 1.0)
Week 4 0.944 (0.75 to 1.0) 0.938 (0.75 to 1.0) 0.943 (0.75 to 1.0) 0.947 (0.74 to 1.0)
Week 8 0.943 (0.70 to 1.0) 0.937 (0.73 to 1.0) 0.948 (0.73 to 1.0) 0.953 (0.77 to 1.0)
Week 16 0.953 (0.67 to 1.0) 0.944 (0.78 to 1.0) 0.949 (0.78 to 1.0) 0.962 (0.79 to 1.0)
Week 24 0.950 (0.61 to 1.0) 0.953 (0.73 to 1.0) 0.948 (0.73 to 1.0) 0.959 (0.76 to 1.0)
Week 48 0.973 (0.80 to 1.0) 0.980 (0.84 to 1.0) 0.973 (0.84 to 1.0) 0.977 (0.85 to 1.0)
CCA
Baseline 0.936 (0.68 to 1.0) 0.924 (0.62 to 1.0) 0.935 (0.59 to 1.0) 0.924 (0.66 to 1.0)
Week 4 0.936 (0.66 to 1.0) 0.931 (0.75 to 1.0) 0.939 (0.46 to 1.0) 0.932 (0.71 to 1.0)
Week 8 0.932 (0.64 to 1.0) 0.931 (0.72 to 1.0) 0.944 (0.49 to 1.0) 0.940 (0.74 to 1.0)
Week 16 0.944 (0.65 to 1.0) 0.936 (0.78 to 1.0) 0.949 (0.58 to 1.0) 0.950 (0.73 to 1.0)
Week 24 0.943 (0.62 to 1.0) 0.941 (0.75 to 1.0) 0.950 (0.67 to 1.0) 0.946 (0.68 to 1.0)
Week 48 0.971 (0.82 to 1.0) 0.974 (0.84 to 1.0) 0.974 (0.77 to 1.0) 0.972 (0.75 to 1.0)
TABLE 41 Adjusted QALY gain over 16 weeks by analysed population and HRQoL utility measure (EQ-5D-3L vs. EQ-5D-5L)
Analysis
Treatment group, adjusted QALY gain (95% CI)
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TABLE 42 Threshold price for the qHPV vaccine over 16 weeks as add-on to PDX cream at three different WTP
threshold values
Measure Incremental QALYs £30,000/QALY £20,000/QALY £10,000/QALY
ITT analysis
EQ-5D-3L 0.0016 48.20 32.10 16.10
EQ-5D-5L Dominated N/A N/A N/A
PPA without change in allocated topical treatment
EQ-5D-3L 0.0072 214 143 71.50
EQ-5D-5L Dominated N/A N/A N/A
CCA
EQ-5D-3L 0.0002 4.48 2.99 1.49
EQ-5D-5L Dominated N/A N/A N/A
N/A, not applicable.
TABLE 43 Factor-specific cost-effectiveness results per analysed population: week 48
Treatment






warts present EQ-5D-3L EQ-5D-5L EQ-5D-3L EQ-5D-5L
Factor at the margins of the vaccine (qHPV vs. placebo)
ITT analysis
Placebo 0.00 0.00 0.00 Reference Reference Reference Reference
qHPV 208.00 171.00 163.00 –0.0048 –0.0048 Dominated Dominated
PPA without change in allocated topical treatment
Placebo 0.00 0.00 0.00 Reference Reference Reference Reference
qHPV 217.00 175.00 173.00 –0.0003 –0.0016 Dominated Dominated
CCA
Placebo 0.00 0.00 0.00 Reference Reference Reference Reference
qHPV 215.00 193.00 181.00 –0.0061 –0.0057 Dominated Dominated
Factor at the margins of the topical creams (PDX vs. IMIQ)
ITT analysis
IMIQ 0.00 0.00 0.00 Reference Reference Reference Reference
PDX –58.50 –50.40 –77.60 0.0046 0.0036 Cost saving Cost saving
PPA without change in allocated topical treatment
IMIQ 0.00 0.00 0.00 Reference Reference Reference Reference
PDX –88.20 –88.10 –123.20 0.0148 0.0092 Cost saving Cost saving
CCA
IMIQ 0.00 0.00 0.00 Reference Reference Reference Reference
PDX –59.00 –45.90 –70.80 0.0048 0.0035 Cost saving Cost saving
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TABLE 44 Factor-specific cost-effectiveness results per analysed population: week 16
Treatment






warts present EQ-5D-3L EQ-5D-5L EQ-5D-3L EQ-5D-5L
Factor at the margins of the vaccine (qHPV vs. placebo)
ITT analysis
Placebo 0.00 0.00 0.00 Reference Reference Reference Reference
qHPV 149.00 154.00 146.00 –0.0072 –0.0063 Dominated Dominated
PPA without change in allocated topical treatment
Placebo 0.00 0.00 0.00 Reference Reference Reference Reference
qHPV 156.00 153.00 153.00 –0.0064 –0.0057 Dominated Dominated
CCA
Placebo 0.00 0.00 0.00 Reference Reference Reference Reference
qHPV 152.00 164.00 156.00 –0.0081 –0.0111 Dominated Dominated
Factor at the margins of the topical creams (PDX vs. IMIQ)
ITT analysis
IMIQ 0.00 0.00 0.00 Reference Reference Reference Reference
PDX –55.40 –56.30 –65.80 0.0080 0.0029 Cost saving Cost saving
PPA without change in allocated topical treatment
IMIQ 0.00 0.00 0.00 Reference Reference Reference Reference
PDX –76.10 –75.00 –89.30 0.0097 0.0030 Cost saving Cost saving
CCA
IMIQ 0.00 0.00 0.00 Reference Reference Reference Reference
PDX –55.50 –53.80 –61.10 0.0079 0.0025 Cost saving Cost saving













PDX plus placebo 460 407 335 0.56 Reference
IMIQ plus placebo 514 457 395 0.54 Dominated
PDX plus qHPV 608 555 476 0.67 1340; 1350; 1280a
IMIQ plus qHPV 665 617 548 0.56 Dominated
a ICERs show the incremental costs per QALY gained for all three cost scenarios: the planned study visits (four within
16 weeks and six within 48 weeks); the actual number of planned and additional visits; the number of visits when
warts were reported to be present.
Incrementally calculated values as an intermediate step are shown in Table 37.
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TABLE 46 Multivariate linear regression models (ITT population): pooled estimates from 50 multiply imputed data sets using Rubin’s rules
Factor
EQ-5D-3L utilities (mapped) EQ-5D-5L utilities
Week 16 Week 48 Week 16 Week 48
Estimate (SE) p-value Estimate (SE) p-value Estimate (SE) p-value Estimate (SE) p-value
qHPV vs. placebo
Intercept 0.3743 (0.0280) < 0.0001 0.5390 (0.0272) < 0.0001 0.2288 (0.0245) < 0.0001 0.4050 (0.0243) < 0.0001
Vaccine group (1 if qHPV) –0.0072 (0.0072) 0.321 –0.0048 (0.0070) 0.492 –0.0063 (0.0046) 0.167 –0.0048 (0.0045) 0.279
Gender (1 if male) –0.0010 (0.0077) 0.893 –0.0030 (0.0074) 0.688 0.0051 (0.0050) 0.307 0.0031 (0.0048) 0.519
Age –0.0005 (0.0004) 0.177 –0.0006 (0.0004) 0.103 –0.0004 (0.0002) 0.083 –0.0006 (0.0002) 0.018
Previous warts –0.0050 (0.0075) 0.504 –0.0052 (0.0073) 0.474 –0.0039 (0.0047) 0.408 –0.0017 (0.0047) 0.721
HIV status –0.0820 (0.0233) < 0.001 –0.1055 (0.0225) < 0.0001 –0.0324 (0.0148) 0.030 –0.0604 (0.0144) < 0.0001
Baseline HRQoL score 0.6231 (0.0262) < 0.0001 0.4642 (0.0251) < 0.0001 0.7810 (0.0235) < 0.0001 0.6085 (0.0231) < 0.0001
AIC (95% CI) –1129 (–1151 to –1093) –1168 (–1195 to –1129) –1593 (–1617 to –1560) –1621 (–1648 to –1573)
BIC (95% CI) –1096 (–1117 to –1059) –1134 (–1162 to –1096) –1559 (–1583 to –1526) –1587 (–1615 to –1539)
Adjusted R2 (95% CI) 0.600 (0.538 to 0.657) 0.487 (0.416 to 0.554) 0.747 (0.702 to 0.787) 0.666 (0.610 to 0.716)
IMIQ vs. PDX
Intercept 0.3649 (0.0286) < 0.0001 0.5333 (0.0278) < 0.0001 0.2230 (0.0249) < 0.0001 0.3993 (0.0248) < 0.0001
Cream group (1 if PDX) 0.0080 (0.0074) 0.280 0.0046 (0.0071) 0.515 0.0029 (0.0046) 0.538 0.0036 (0.0045) 0.421
Gender (1 if male) –0.0009 (0.0077) 0.903 –0.0029 (0.0074) 0.694 0.0051 (0.0050) 0.301 0.0032 (0.0048) 0.510
Age –0.0005 (0.0004) 0.188 –0.0006 (0.0004) 0.107 –0.0004 (0.0002) 0.087 –0.0005 (0.0002) 0.020
Previous warts –0.0050 (0.0075) 0.501 –0.0052 (0.0073) 0.472 –0.0039 (0.0048) 0.409 –0.0017 (0.0047) 0.720
HIV status –0.0827 (0.0233) < 0.001 –0.1059 (0.0225) < 0.0001 –0.0326 (0.0149) 0.029 –0.0607 (0.0144) < 0.0001
Baseline HRQoL score 0.6247 (0.0264) < 0.0001 0.4651 (0.0253) < 0.0001 0.7822 (0.0236) < 0.0001 0.6099 (0.0232) < 0.0001
AIC (95% CI) –1130 (–1151 to –1094) –1168 (–1196 to –1129) –1591 (–1615 to –1559) –1620 (–1647 to –1572)
BIC (95% CI) –1096 (–1117 to –1061) –1134 (–1162 to –1096) –1558 (–1582 to –1525) –1587 (–1613 to –1538)
Adjusted R2 (95% CI) 0.601 (0.538 to 0.658) 0.487 (0.416 to 0.554) 0.747 (0.701 to 0.786) 0.666 (0.610 to 0.715)












































PDX plus placebo 689 654 473 0.71 Reference
IMIQ plus placebo 743 696 541 0.74 1800; 1400; 2270a
PDX plus qHPV 892 817 627 0.72 Dominated
IMIQ plus qHPV 956 875 714 0.81 3040; 2560; 2470a
a ICERs show the incremental costs per QALY gained for all three cost scenarios: the planned study visits (four within
16 weeks and six within 48 weeks); the actual number of planned and additional visits; the number of visits when
warts were reported to be present.
Incrementally calculated values as an intermediate step are shown in Table 38.
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